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ABSTRACT OF THE THESIS
A PILOT STUDY EXAMINING THE DIFFERENCE IN COMMUNITY
MENTAL HEALTH SERVICE USERS’ SYMPTOMATOLOGY AND
CONCORDANCE WITH MEDICATION REGIMENS AFTER COMPLETION OF
THE QUATRO ADHERENCE THERAPY INTERVENTION
by
Stephanie Hall Ford
Florida International University, 2004
Miami, Florida
Professor Kathryn Hoehn Anderson, Major Professor
A randomized, experimental pilot study of QUATRO Adherence Therapy
examined differences at baseline and follow up in the dependent variables of severity of
psychiatric symptomatology and medication concordance as measured by the Positive
and Negative Symptom Scale and the Personal Evaluation of Transitions in Treatment for
subjects with schizophrenia and schizoaffective disorder at a community mental health
center. The sample was 23 subjects. A questionnaire developed for the study collected
data at follow-up. Data were analyzed using descriptive statistics, /-tests, and repeat
Anova to compare groups and determine significance of change following completion of
the intervention. Program evaluation was positive. Statistical comparison indicated no
significant differences were found in change scores for either group. Implications for
further research are that a larger scale randomized controlled study is needed to produce
statistical significance.
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Chapter 1
Introduction
Living with a mental illness, such as schizophrenia, characterized by psychosis is
the life experience of approximately 2.2 million American adults (Narrow, as cited in
National Institute of Mental Health [NIMH], 2002). Consider that each of these 2.2
million adults has family members and the number affected by this illness rises to 2.2
million families. Recently the World Health Organization (WHO) characterized active
psychosis as producing a disability equivalent to that of quadriplegia and causing a
burden of 2.3 million lost years of healthy life worldwide (Murray, & Lopez, 1996). The
importance of schizophrenia as an illness requiring improved treatments cannot be
underestimated.
Through the centuries, people with mental illness, who have been unable to care
for themselves, have been outcast, or placed in the care of their families, religious orders,
prisons, state hospitals, and more recently the communities in which they live.
Schizophrenia and schizoaffective disorder are included in the schizophrenias or
psychotic disorders for classification in the Diagnostic and Statistic Manual ofMental
Disorders - IV Revised (DSM-IV R)(American Psychiatric Association [APA], 2001)
and are chiefly characterized by disabling positive symptom of psychosis and a cluster of
“negative” symptoms within a context of impaired social functioning.
The positive symptoms of psychosis are collectively described as a loss of contact
with reality (National Health Services [NHS], 2004). Symptoms include hallucinations
(hearing, seeing, smelling or feeling things that do not exist), and delusions (bizarre, false
beliefs) (NHS). Severe thought disturbances and grossly abnormal behavior are also
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defined as psychotic (NHS). Negative symptoms of schizophrenia can include; social
withdrawal, lack of initiative, poor motivation, and paucity of thought. Until the 1950s,
there were no effective treatments for schizophrenia. Theories of the brain’s chemical
neurotransmitter system gone awry have led to ongoing improvements in medications
used to treat this illness since the 1950s (Seeman & Seeman, 2002).
From the 1950s through the 1980s, medications now referred to as typical
antipsychotics were used to treat symptoms of psychosis (Mycek, Harvey, & Champ,
2000). Side effects, especially movement disorders, from these neuroleptic medications
led to metaphors such as the thorazine shuffle to describe the dull-eyed stare and stiff
legged walk, suffered by many individuals taking these medications (Goode, 2003).
Advances in pharmacological efficacy over the past 10 years have reduced these types of
side effects dramatically with a group of medications called atypical antipsychotics
(Seeman & Seeman, 2002)
Research reveals that antipsychotic medications used in the treatment of psychotic
disorders are effective in reducing the symptoms of psychosis (The Schizophrenia Patient
Outcomes Research Team [PORT], 1998). Taken according to a prescribed regimen, they
may prevent these symptoms from returning (PORT). Antipsychotic medications reduce
the symptoms of schizophrenia, but as with many illnesses, medication is only one part of
the treatment strategy. Current treatment recommendations of community based
psychosocial interventions paired with medications for people with schizophrenia result
in better health outcomes and fewer relapses (McGuire, 2000; Oehl, Hummer, &
Fleischhacker, 2000; PORT, 1998).
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Community-based psychosocial interventions focus on two major areas of
treatment; remediation of both the psychological and the social impact of schizophrenia.
Medication can greatly reduce and even eliminate symptoms of psychosis but many
individuals also experience the added difficulty of cognitive impairment, difficulty
concentrating, and reduced psychomotor processing. These cognitive impairments are
associated with the negative symptoms of schizophrenia such as: blunted affect,
emotional withdrawal, poor rapport, social isolation, obstacles to abstract thinking, lack
of spontaneity, and stereotyped thinking. Cognitive impairments are associated with
difficulties managing social relationships, maintaining employment, functioning
independently, and are not responsive to medications (Hughes et al., 2002). Community
based treatment for schizophrenia, combining medication with social and cognitive
interaction may more effectively treat the illness and has the potential to impact
successful community living of individuals with schizophrenia (Sensky et al., 2000).
Background of the Problem
The World Health Organization (2003) reports that non-adherence to treatment
across chronic diseases is a worldwide problem of great magnitude. The striking
dilemmas caused by non-adherence include the morbidity of treatment resistance and
appreciably increased health care costs (WHO). Support for the WHO’s findings and
initiatives regarding adherence abound in the literature.
The effectiveness of antipsychotic medication for treatment of schizophrenia is
well established in the literature, but compliance rates are less than is desirable for the
control of symptoms (Oehl et al., 2000). Across all illness categories, rates of medication
compliance range from 24% to 90% (Cramer, & Rosenheck, 1998). Generally, people do
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not take medications as prescribed by their health care providers, whether the
medications are antibiotics, cardiac medications, or antipsychotics (Cramer, &
Rosenheck; Jarboe, 2002; McCabe, 2002; PORT, 1998).
Hospitalization for the exacerbation of symptoms of schizophrenia is regularly
associated with individuals not taking antipsychotic medications in accordance with
prescribed regimens (Agarwal, Sharma, & Kumar, 1998; PORT, 1998). It is estimated
that failure to take antipsychotic medications as prescribed contributes to approximately
40% of the annual costs of hospitalization for individuals with schizophrenia (Weiden, &
Olfson, 1995). Amplifying the financial costs are the distressing human costs of life
disruption, residential and employment instability, sub-optimal clinical response, poor
continuity of care and relationship instability that accompany frequent hospitalizations
(McCabe, 2002; Weiden, & Olfson). Further, the length of time to achieve symptom
remission takes longer with each respective hospitalization (Beers, & Berkow, 2004).
Service users with schizophrenia, their families, and their communities bear the burdens
of the significant social and economic impact of poor treatment concordance.
Since 1996, research concerning improving medication concordance has focused
on therapies based on cognitive behavioral therapy and motivational interviewing (Gray,
Wykes, & Goumay, 2003). An intervention of compliance therapy was developed, based
on the principles and techniques of these two therapeutic approaches (Kemp, Kirov,
Everitt, Hayward, & David, 1998). Years of research developing compliance therapy
(Kemp, Hayward, Applewhaite, Everitt, & David, 1996; Gray, David, & the Quatro
Research group, 2001) combined with the efforts of the Quatro research group have
resulted in the development of a new intervention called Quatro Adherence Therapy
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(QAT). Quatro refers to the four countries in the European Union participating in the
development and research of this intervention.
Experimental studies of new interventions that increase concordance with
prescribed medication regimens will provide needed evidence-based practice guidelines
and standards of care for clinicians. Quatro Adherence Therapy is designed to address the
complex and individual variables associated with poor concordance (Gray, & Odunlade,
2002). This thesis represents the introduction of a QAT intervention in the United States.
Purpose
The purpose of this pilot study was to demonstrate whether any changes in
severity of symptomatology or mediation concordance occurred as a result of adding an
intervention of Quatro adherence therapy to service users’ usual treatment at a local
community mental health center. The pilot study provided a previously tested
intervention as an adjunct to participants’ current treatment. Dr. Richard Gray, research
fellow at King’s College London, assisted the principal investigator with QAT training,
and provided the QAT Training Manual for use with this study (see Appendix A for copy
of Dr. Gray’s letter of consent).
Research Questions
This pilot study was designed to answer the following questions:
1)

Is there a difference in the severity of symptomatology for service users with
schizophrenia or schizoaffective disorder after participation in the QAT
intervention?
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2)

Is there a difference in medication concordance for service users with
schizophrenia or schizoaffective disorder after participation in the QAT
intervention?

Definition of Terms Used in this Thesis
Schizophrenia. Schizophrenia is a chronic, serious mental illness. A diagnosis of
schizophrenia is based on a clinical picture of overall functioning. Diagnosis requires that
two or more of the following symptoms are evident for a significant portion of time in a
one-month period: (a) delusions, (b) hallucinations, (c) disorganized speech, (d) grossly
disorganized or catatonic behavior, (e) negative symptoms of lack of energy and
motivation, and (f) affective flattening or loss of concentration (adapted from APA, 2001,
p. 312). Diagnosis also requires disturbance of social and occupational functioning, with
the duration of disturbance lasting for at least six months, and the exclusion of substance
abuse or general medical condition as the cause of the disturbance (APA).
Motivational interviewing (MI). Motivational interviewing is a client centered,
directive method of counseling, with a deliberate goal of enhancing intrinsic motivation
to change, through exploration and resolution of ambivalence (Miller, & Rollnick, 2002).
Motivational interviewing is rooted in the core concept of the intrinsic worth of human
beings. This core concept characterizes the ethics of the nurse-client relationship and
advanced practice nursing.
Cognitive behavioral therapy (CBT). Cognitive behavioral therapy is an actionoriented form of talk therapy that focuses on identifying faulty thinking patterns that lead
to maladaptive behaviors, and negative emotions. Maladaptive behavior is behavior that
is counter-productive or interferes with everyday living. The treatment focuses on
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assisting an individual to identify thoughts (cognitive patterns) and assumptions
(irrational beliefs) in order to change his or her behavior and emotional state (FordMartin, 2004).
Quatro Adherence Therapy (QAT). Quatro adherence therapy is a structured,
pragmatic, therapeutic intervention based on the principles and counseling skills of
motivational interviewing and cognitive behavioral therapy. In this intervention, the
mental health worker uses one-on-one therapeutic conversation with the client to develop
importance and confidence, two key components linked to resolving ambivalence about
taking medication. (Gray, David, & the Quatro Research Group, 2003).
Importance, The term importance used in QAT, refers precisely to the value or
significance an individual places in a belief. The context of importance in QAT is defined
by the hypothesis that people tend to maneuver in the direction of their highly valued
beliefs. Thus, decisions about behavior change often reflect self-defined important
values. Therefore, the value of a belief weighs in heavily as a positive component of the
changes that lead to resolving ambivalence (Miller, & Rollnick, 2002).
Confidence. The use of the term confidence in QAT corresponds to the service
user’s self-measurement of their ability to enact change. High confidence levels are equal
to strong beliefs in abilities to change. Therefore, a large amount of confidence helps tip
the scales toward change. Research on MI suggests that high confidence levels are
strongly related to the ability to follow through with actions necessary to implement
decisions (Miller, & Rollnick, 2002).
Nurse-patient relationship (NPR). The nurse patient relationship is a descriptive
term coined by Hildegard Peplau (1952) to denote the construct of nursing practice. The
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NPR is comprised of four components: (a) the nurse, (b) the patient, (c) professional
expertise, and (d) client need. Peplau theorized that (a) the patients’ presenting problems
were identified, (b) an understanding of their problems and patterns was developed, and
(c) the application, and testing of remedial measures occurring within the context of these
four components (1991, p. 13). The goal of the NPR is to arrive at beneficial outcomes
for patients (Peplau, 1952).
Theoretical Framework
The theoretical model guiding this pilot study is Hildegarde Peplau’s theory of
interpersonal relations in nursing. Peplau’s theory proposes that nursing involves a
significant, therapeutic, interpersonal process (Peplau, 1952). Peplau defines the
therapeutic interpersonal process as when a nurse, “helps a patient to identify problematic
elements in his current situation and to discover and understand something about what is
happening to him during his illness” (1952, p. xiv). The QAT program is an example of a
therapeutic, interpersonal process in action. In this pilot study, the collaborative
relationship between the therapist and the individual participating in QAT denotes the
interpersonal process.
Peplau also describes therapeutic interpersonal techniques, as verbal interventions
used by nurses which promote a client’s competencies in, “self-expression, stating
thoughts, describing actions and naming feelings.. .related to resolution of focal attention
dysfunction” (1989b, p.347). Congruent with Peplau’s description, QAT employs
specific peneil-and-paper and verbal interventions aimed at the resolution of ambivalence
through identifying and voicing the client’s unique self-view. These QAT interventions,
which are integral to the interpersonal process, are detailed in Chapter III of this thesis.
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The interpersonal process, common to both Peplau’s theory and QAT’s framework, is the
vehicle for resolution of ambivalence to problematic elements in the individual’s
situation. Through this process, clients explore areas of ambivalence through focusing
their attention on describing experiences and values and increasing self-understanding of
the dynamics present in their illness.
Peplau’s model of nursing is based on the idea that improved health outcomes are
related to clients achieving altered self-views as the present experience is integrated with
other life experiences through self-initiated processes of self-renewal, self-repair and
self-awareness. The outcome is promoted by the experiences in the nurse-patient
relationship (Peplau, 1952). Peplau describes illness events as opportunities for
“experiential learning, self-exploration and growth” (1991, p. 13) and she theorized that
change is required as the individual adjusts to the facts of the illness and incorporates the
experience into a new self-view (1952). In the initial publication of her theory in 1952,
Peplau described four stages of the nurse-patient relationship that she termed: orientation,
identification, exploitation, and resolution. Later, Peplau (1997) published updates to her
theory of nursing which modified the phases of the nurse-patient relationship to
orientation, working, and termination. These three overlapping phases illustrate the
progression of the nurse-patient relationship (Peplau, 1997).
Peplau’s theory of nursing emphasizes a view of the “self as a process, moving in
a direction on a course of personal development, always open to revision... with a
tendency towards a certain stability of self views” (Peplau, 1989a, p. 66). Peplau’s view
of self is congruent with the framework of motivational interviewing used in QAT, which
states that change is a natural human process (Miller, & Rollnick, 2002). Peplau further
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emphasizes that within the context of the interpersonal relationship between nurse and
client, the nurse provides an opportunity for the client to “gradually examine and change
the contents of the self-system by checking self views against reality” (Peplau, 1989c, p.
209),
Peplau also discusses the use of verbal tactics by nurses to undermine the
presenting thought pathology associated with change in the client’s use of language and
thought (1999, p. 270). Peplau’s strategy of verbal tactics is analogous to the use of
cognitive behavioral techniques in QAT to develop discrepancy of thought, referred to as
cognitive dissonance. This CBT technique increases self-awareness of the consequences
of underlying thought patterns and the reasons for making a change in current behavior,
by encouraging the client to express their values and voice their own reasons for taking
medication (Gray, David, et al., 2003).
Three Phases ofNurse Patient Relationship
Orientation phase. The orientation phase initiates the nurse-patient relationship.
Peplau characterizes the orientation phase as a time when the focus is on the patient as
the nurse obtains essential information. The essential information is obtained through the
nurse focusing on listening, assessing, encouraging descriptions and obtaining an
understanding of the patient’s experience (Peplau, 1997). For the purposes of this pilot
study the initial sessions of adherence therapy, including the engagement phase, and
assessment phase, correspond and are consistent with Peplau’s orientation phase. The
underlying principles of Peplau’s theory and QAT emphasize use of active listening
skills, and careful assessment of the client’s health history, perceptions, and experiences.
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Characteristics of human nature that Peplau describes as preconceptions, and
QAT describes as assumptions, refer to forming an opinion about someone before having
a personal experience with that person (Gray, David, et at, 2003; Peplau, 1997). To
establish rapport and a therapeutic interpersonal relationship with the client, these
characteristics are regarded as traps which the nurse or mental health worker must be
vigilant to avoid throughout each encounter (Gray, Wykes, & Goumay, 2003; Peplau,
1997). These characteristics are regarded as traps because they interfere with the
therapeutic process and can be unethical (Corey, 2001). Effective, ethical nursing care is
based on the client’s self report of values and cultural beliefs, which the nurse elicits
rather than assumes to know. The QAT manual admonishes frequently, do not make
assumptions. In a similar manner, Peplau asserts that the preconceptions and stereotypes
inherent in the interpersonal relationship must be examined by the nurse and changed if
necessary (1997).
Working phase. The working phase is the second phase of the nurse-patient
relationship theorized by Peplau (1997). This phase develops as the conversation changes
to focus on the patient’s reactions to illness and the work needing to be done by the
patient in order to regain health (Peplau). In this phase, Peplau depicts the nurse
employing health teaching and enhancing learning for the patient by building on what the
patient already knows or experiences (1997). In this phase, the nurse draws on the skills
of attentive listening and inquiry to encourage greater self-understanding in the patient
(Peplau, 1997, p. 164).
Peplau’s working phase is distinguished by the concepts of facilitating greater
self-understanding and struggling with the problem, not the person (Peplau, 1997, p.
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164). Quatro Adherence therapy’s therapeutic phase corresponds and is consistent with
Peplau’s working phase. Quatro adherence therapy guides the nurse to facilitate the selfexpression and struggling with fears about medication without judgment or labeling, thus
allowing a struggle with the problem, not the client to ensue (Gray, David et al., 2003).
Peplau believed that, “attentive listening to the patient’s narrative of a personal
experience allows for greater self understanding in the patient” (1997, p. 164). This
approach is compatible with QAT’s use of social learning theory embedded in a
motivational interviewing perspective: “As I hear myself talk, I learn what I believe”
(Miller, & Rollnick, 2002, p. 21).
Further, Peplau emphasizes that psychotherapeutic approaches are persistently
applied and have a demonstrable impact on that item of the client’s behavior, which is
either an asset or pathology (1999, p. 264). This is consistent with the QAT counselor
skill base important to each phase of the therapy. Consistent use of (a) agenda setting to
align expectations, (b) accurate reflective listening to reinforce self-generated positive
statements about medication, and (c) eliciting or developing discrepancy to identify the
pathology of cognitive dissonance, are three of several QAT approaches that impact
ambivalence (Gray, David, et al., 2003, p. 12). Ambivalence is the hidden asset in each
client and it is the starting point of change.
Termination phase. The termination phase is the third and final phase of the
nurse-patient relationship (Peplau, 1997). This phase begins in the previous orientation
and working phases when interactions intermittently focus on the limits of the
interpersonal relationship. A summary of the work, the significant findings, and the
outcomes emerging from the interpersonal relationship characterize the final phase.
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Providing a sense of closure in relation to the work accomplished through the
interpersonal relationship is an important step in this final phase. (Peplau, 1997, p. 165).
The evaluation phase of adherence therapy, which summarizes and considers
progress, is the counterpart of Peplau’s termination phase involving summarizing and
providing closure (Peplau, 1968). Quatro adherence therapy defines the termination
phase, which usually concludes in the final therapy session, as a review of: (a) treatment
to date; (b) practical problems identified and any resolution of these; (c) side effects
experienced; (d) client’s readiness to take medication; (e) client’s rating of importance
and confidence in taking medication; (f) beliefs about medication, and (g) any plans made
based on resolved ambivalence (Gray, David, et al., 2003). This summary of the
assessment and the related concepts explored during therapy is consistent with Peplau’s
definition of the termination phase. Quatro adherence therapy’s evaluation phase
provides validation of the individual’s expressed experience and closure of the
therapeutic process.
The literature identifies ambivalence and lack of insight, or faulty understandings,
as factors associated with poor medication concordance and exacerbation of symptoms
(Gray, Robson, & Bressington, 2002). Resolution of ambivalence, positive practitionerclient relationship, and good insight are associated with a high level of treatment
concordance and a reduction in symptoms (Gray, Wykes, Edmonds et al., 2002).
Therefore, this model of QAT used as a nursing intervention to resolve ambivalence
resulting in a reduction of symptoms follows Peplau’s model of therapeutic
communication in interpersonal relations which leads to the improved health and well
being outcomes stressed in her theoretical framework (Peplau, 1952).
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Significance
This pilot study was significant to advanced nursing practice for several reasons.
As described in this chapter, even with care and treatment, many people with
schizophrenia suffer distressing symptoms that disrupt their thoughts, emotions, and
ability to function independently, and places them at a high risk for suicide (Simon,
2002). Research suggests that medication combined with psychosocial interventions for
people with schizophrenia make a significant impact on health outcomes and assist some
individuals to recover a relatively higher level of social functioning (McCann, 2001).
Investigating and focusing on relapse-prevention interventions is critical because
of the demoralization that occurs with successive exacerbations for individuals with
schizophrenia (Kane et al., 2004). This pilot study contributed the beginnings of research
in the U.S. for QAT, an evidence-based program of care delivery for people with
schizophrenia that promotes concordance, a reduction of symptomatolgy and aims to
minimize the complications concomitant with poor treatment concordance in
schizophrenia.
The body of literature relating to medication adherence includes a number of
terms; compliance, adherence, and concordance. Although the longstanding term of
compliance and the newer term of adherence feature prominently in the literature, it is
proposed, that use of the term concordance more accurately describes the goals and
experiences clinicians seek to develop with clients regarding medication regimens
(Bebbington, 1995; Gray, Wykes, & Goumay, 2002). The word concordance is preferred
and used in this thesis to reflect issues of compliance and adherence. However, when
describing studies cited in this thesis the term used in the original work was utilized.
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Concordance with a prescribed medication regimen implies that a state of mutual
agreement exists between the health practitioner and the client. Concordance with a
negotiated medication regimen is one of the goals of pharmacological treatment for
schizophrenia and schizoaffective disorder.
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Chapter II
Literature Review
Introduction
Literature regarding the significant impact of schizophrenia on life functioning
has its beginnings before 2000 BC, and ranges in concept from global impact studies to
molecular biology. Theories of the etiology of schizophrenia fluctuate from demonic
possession to irregularities in the expression of receptors on nerve cell membranes. What
is clear is that throughout history, the illness of schizophrenia has caused serious
economic and personal burdens for individuals with this illness and their families (Grob,
1998; van Wijngaarden et al., 2003).
Since the second half of the twentieth century technology, science, and human
nature have contributed vastly to improved treatments for this illness, leading to recovery
for many individuals. Pharmacological interventions greatly reduce the hospitalization
and morbidity associated with schizophrenia. However, many people do not take their
medication as prescribed by their health care providers, including people with
schizophrenia. Reasons why people do not take medications in accordance with the
prescription are extremely complex and individual (Gray, & David, on behalf of the
European Quatro Research Group, 2001; WHO, 2003).
The variables contributing to poor medication concordance for people with
schizophrenia have been studied and used as the basis for developing therapeutic
interventions. In recent studies, an intervention of QAT has been associated with
improved outcomes for people with schizophrenia. Through the study of the effectiveness
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of interventions, practitioners gain greater understanding of the etiology of the illness and
may create improved treatments.
In just over 4000 years of recorded human history, the strides made in recovering
from this illness are tremendous. However, health care workers are still overheard
remarking, “Those people with schizophrenia, must have the devil in them” (personal
experience, May 16, 2004).
History of Schizophrenia
Psychotic symptomatology and schizophrenic-like syndromes have been written
about since ancient civilizations recorded descriptions of this illness before 2000 BC, in
the ancient Egyptian Book of Hearts. The Greek physician Hippocrates dismissed the
idea of a demonic cause of psychosis, instead suggesting that disorders of madness
originated entirely from the brain. From the Middle Ages through the 1700s, witchcraft
and demonic possession were considered the malevolent influences causing odd
behavioral and thought disturbances (Korn, 2001).
In the medical community, psychiatric theory in the early 1800s began to focus
again, as Hippocrates had, on the brain being the origin of mental disorders. By the late
1800s, German psychiatrist Emil Kraepelin combined numerous symptoms under a single
diagnosis - dementia praecox (dementia of early life). Ten years later, Swiss psychiatrist
Eugene Bleuler, coined the term schizophrenia referring to the splitting or fragmentation
of an individual's thinking and feeling processes. At the start of the 1900s, a prevailing
hypothesis was developing that all mental reactions had physiological counterparts
(Grob, 1998).
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In 1949, the American Psychiatric Association collaborated with the New York
Academy of Medicine resulting in the Diagnostic and Statistical Manual ofMental
Disorders (JDSM-T), which was published in 1952. The classifications viewed psychiatric
disorders as reactions of the personality to psychological, social, and biological factors.
Two studies started in 1961 have suggested that new drug therapies were particularly
effective in dealing with severe mental disorders (Grob, 1998). However, one opposing
view existed within the medical community during the 1960s. Physician Thomas Szasz,
argued that, “mental illness is a myth whose function it is to disguise and thus render
more palatable the bitter pill of moral conflicts in human relations” (Szasz, 1960, p. 263).
The 1980s and 1990s brought a revolution in technological advancement and
neurobiological inquiry (Murray, & Lopez, 1996). Today, in many ways, the health care
community has come full circle to Hippocrates’ physical basis of mental disorders, but
with a greater understanding that there are many facets of this complex syndrome the
medical community diagnoses as schizophrenia.
The Experience of Schizophrenia
The lived experience of schizophrenia offers a compelling description of how
debilitating schizophrenia can be for those living with the illness. Phenomenological
study describes aspects of a health situation as experienced by the person in it. Spence
(2002) reviewed the clinical phenomenology of schizophrenia drawing connections with
his 1997 (Spence et al.) study of the neural correlates of the experience of alien control.
The occurrence of alien control in schizophrenia involves experiencing thoughts or
movements as controlled by an outside force. This characteristic experience of
schizophrenia is described clinically as a loss of subjectivity (Spence, 2002). Some
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individuals with schizophrenia describe this as an experience of unidentifiable external
influence that causes their intimate thoughts to be, “interfered with” directly, their moods
to be, “put into them” from the outside and their physical movements, “belonging] to”
another person (Spence, 2002).
The distorted perceptions involved in psychosis are described poignantly in the
following observation: “She stares closely at people but asks that they do not look back at
her. If they do, she seems to hear “voices” in the perceived movements of their eyes, or to
experience others’ thoughts as entering her head. She asks repeatedly what this means”
(Spence, 2002, p. 164). These distorted perceptions experienced in schizophrenia may
contribute to difficulty in recognizing the return of symptoms. These distortions were
described in a doctoral student’s first-person account of the relapse of psychosis. He
noted that the relapse of his symptoms was so subtle it went unnoticed by colleagues. He
related the following, “All of my consciousness seemed somehow externalized to the rest
of the world at the same time. It was as though these thoughts, sensations, and even old
childhood memories were not my own but instead community property” (W., 2002, p.
747). These descriptions from people who live with schizophrenia, along with brain
scans, convince some researchers that the neural system correlated with the sense of self,
especially the right parietal cortex of the brain, is implicated in the etiology of some
symptoms of schizophrenia (Spence, 2002).
Neurobiological Theories of Schizophrenia
Perceptions, emotions, and physical sensations are all coordinated in the complex
neural circuits of the brain. The mesolimbic section of the brain is thought to be involved
in regulating emotions, beliefs, and sensations, although this is poorly understood
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(Keltner, 2002). The clinical effects of antipsychotic medications are thought to be due to
the competitive blocking of the neurotransmitter dopamine’s receptors on nerve cells in
the brain (Mycek, et al. 2000). When subsets of dopamine receptors, D2 receptors, are
blocked at a minimum of 65% in the mesolimbic section of the brain, positive symptoms
of schizophrenia are alleviated (Katzung, 2001; Mycek, et al.).
The theory of an excess of the neurotransmitter dopamine has evolved to describe
the etiology of schizophrenia because blocking of dopamine is associated with a decrease
in positive symptoms. In his textbook of psychopharmacology, Keltner notes this
therapeutic dopamine blocking is not effective for some individuals and is not effective
for treating the entire spectrum of schizophrenia’s symptoms. Conversely, the negative
symptoms of schizophrenia are associated with a relative deficit of dopamine in the
mesocortical tract of the brain (Keltner, 2002). There is more involved in the pathology
of schizophrenia than the theory of excess dopamine can explain. Increased
understanding of the brain chemistry and neural logistics involved in regulating specific
human activities has led to wider, more complex theories regarding the etiology of
schizophrenia.
Studies seeking to isolate causes and gain a better understanding of the disruption
in brain functions related to schizophrenia may lead to improved treatments in the future.
N-methyl-D-aspartate (NMDA) receptors, which play a critical role in healthy nerve
development and long-term memory consolidation, may be abnormal in schizophrenia
and are currently under study (Abi-Saab, D'Souza, Moghaddam, & Krystal, 1998; Jensen,
Idiart, & Lisman, 1996). NMDA dysfunction is associated with synaptic runaway, a
process involving excess, erroneous nerve connections that leads to faulty memory
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processing and cognitive difficulties (Greenstein-Messica, & Ruppin, 1998). These faulty
connections are made in nerve networks associated with activity-dependent learning.
Sensory experiences are associated with neuronal activity in the brain’s neocortex. The
neocortex is associated with cognitive functions such as, learning, memory, and
perception. Neuronal activity is characterized by the interactions of neurons emitting and
processing electric signals via their synaptic connections (Benuskova, 2000). Event or
sensory experience induced changes in neuronal interactions have been demonstrated by
Hoffman and McNaughton (2002). Gradually these event-related changes in neuronal
associations are established in the neocortex through a process of automatic repetition
(usually during sleep). Thus, learning and memory consolidation is dependent on this
neuronal activity. Neurons form memories through a process of sequentially reinforcing
synaptic connections, which shape neuronal networks (Fries, Fernandez, & Jensen,
2003). The inability to process memories and perceptions correctly and order thought
processes in a logical manner is consistent with both synaptic runaway and many
symptoms of schizophrenia.
Dopamine is thought to enhance the process of synaptic runaway. This may
explain why antipsychotic dopamine blocking agents are frequently effective and take
weeks to exert their therapeutic effects (Greenstein-Messica, & Ruppin, 1998). Blocking
dopamine may allow these activity-dependent learning nerve networks over time to self
prune erroneous connections and establish accurate connections. Synaptic runaway may
play a very important role in the pathogenesis of schizophrenia (Greenstein-Messica, &
Ruppin) and indicates support for models of treatment that include medication, as well as
supportive learning environments.
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One way to view the results of synaptic runaway on an individual’s functioning
may be evident in the study of auditory hallucinations. Disrupted or faulty connections
between nerve cells are observed in schizophrenia (Simon, 2002). Auditory
hallucinations involve activation in the brain of several functional systems which
resembles a model of auditory hallucinations as memories of speech interpreted
incorrectly (Copolov et al., 2003). Steady state probe topography (SSPT) is a brain
mapping technique used to track electrical activity in the brain’s cortex. The technique
shows significant sensitivity to cognitive activity, and insensitivity to EEG artifact
(Silberstein, Burkitt, & Wood, 1993, as cited in Line, Silberstein, Wright, & Copolov,
1998). Mapping the electrical impulses with SSPT, using a rapid (split second) time scale
shows that the right temporo/parietal region is involved with the cognitive interpretation
of auditory hallucinations (Line et al.).
Interestingly, self-recognition is associated with this cortical region and may help
explain how faulty nerve networks process a non-auditory stimulus (a memory of speech)
that appears to be self-generated into an auditory perception (Line et al. 1998). The
complex relationship of logistics and neurotransmitters in the brain is also associated with
a decreased communication network between the right and left sides of the brain in
individuals with schizophrenia (Simon, 2002). Irregularities in NMDA molecules, nerve
networks, neurotransmitters, and brain structure appear to all play a role in the
impairment of mental function and etiology of negative and positive symptoms of
schizophrenia. Not surprisingly, these multiple atypical brain insults contribute to the
negative and positive symptoms of schizophrenia and to the enormous difficulties of
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many individuals with schizophrenia to negotiate daily life with active symptoms
(Copolov et al., 2003; Greenstein-Messica, & Ruppin, 1998; Line et ah; Sinton).
Efficacy of Pharmacological Interventions
Over 100 clinical trials and numerous studies have demonstrated the efficacy of
the use of antipsychotic medications for treatment of the symptoms of schizophrenia
(Kane et ah, 2004; PORT, 1998; Sechter, Peuskens, Fleurot, Rein, & Lecrubier, 2002).
Efficacy in real terms means a reduction or elimination of many symptoms, with a higher
efficacy in the reduction of positive symptoms (Kane et ah; Sechter et ah), such as
auditory hallucinations, paranoia, and disorganized speech.
There is also significant evidence to suggest that the continued use of
antipsychotic medication, after the remission of symptoms, will prevent recurrence of
symptoms and reduce the long-term severity of both positive and negative symptoms
(Kane et ah, 2004; PORT, 1998; Seeman, & Seeman, 2002). Davis and Andriukutis’
meta-analysis of antipsychotic treatment shows a relapse rate of 16% with medication,
compared to a 60% relapse rate on placebo (1986, as cited in Agarwal et ah, 1998). In a
study assessing the impact of dose reduction of antipsychotic medication and family
treatment during maintenance treatment, 313 participants at five outpatient centers were
treated and assessed for 2 years. Both continuous low-dose and targeted treatment for
emergent symptoms led to an increased use of rescue medication and relapse (Schooler,
Keith, & Severe, 1997). These findings are further confirmation of the value of
uninterrupted use of antipsychotic medication in preventing relapse and rehospitalization.
Although medication is not a cure for schizophrenia, it is clearly an important,
critical aspect of treatment resulting in a reduction of symptoms for many individuals. In
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a 1-year study of drug therapy patterns and treatment costs for 18,090 individuals
receiving outpatient care for schizophrenia with Medicaid insurance it was found that,
“all antipsychotic drug use patterns, except uninterrupted therapy, were found to be
associated with significantly higher total health care costs” (Lyu, McCombs, Johnstone,
& Muse, 2001, p. 93). Yearly direct care costs for treatment of relapse in schizophrenia in
the United States are estimated at roughly 800 million dollars (Weiden, & Olfson, 1995).
The financial costs are striking and are suggestive of the even more striking personal
costs associated with relapse for individuals with schizophrenia and their families.
Psychosocial Impact of Relapse
Relapse of active illness in schizophrenia concomitant with exacerbation of symptoms is
associated with poor medication compliance for approximately 40% of individuals who
relapse (Weiden, & Olfson, 1995). As a group, individuals with schizophrenia who
experience multiple relapses and active psychosis have an increased risk of homelessness,
victimization, a poorer prognosis, and longer times to remission of symptoms
(Pinikahana, Happell, Taylor, & Keks, 2002; Seeman, & Seeman, 2002).
Active psychosis interferes with every aspect of daily living for both the
individual with schizophrenia and their families (WHO, 2003). One study stretching
across five countries of the European Union (EU) concluded that caregivers are
constantly coping with the consequences of this illness. Four emotional factors emerged
from this study as common to all caregivers and they are descriptive of the caregiver role.
They include: tension, worrying, supervision, and urging. This caregiver worry and
tension exists in the context of the many serious legal consequences of schizophrenia for
individuals with this illness (van Wijngaarden et al. 2003).
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According to Brekke, Prindle, Bay, & Long (2001) individuals with schizophrenia
and schizoaffective disorder are said to be at a 65% to 134% higher risk of being the
victim of a crime than the general public. This study followed 172 individuals with
schizophrenia over a three-year period, and the authors found that, among other factors,
decreased social functioning and poor medication adherence are related to police contact,
in the form of victimization or arrest. During the study, 38% of the participants with
schizophrenia were the victims of crime, of which 91% were violent crimes. This statistic
supports Link, Andrews and Cullen’s (1992) finding that when psychosis is controlled
for, mentally ill individuals have no greater risk for illegal behavior or violence than does
the average person. This aspect is important in supporting the urgency for increased
medication concordance associated with fewer symptoms of psychosis, and a lower rate
of victimization.
Recent publication of treatment guidelines for schizophrenia, developed through
systematic review of research-based evidence and expert opinion, support the use of
antipsychotic medications for reducing the symptoms, morbidity and mortality associated
with schizophrenia. (McEvoy, Scheifler, & Frances, 1999; PORT, 1998). The importance
of preventing relapse can be life saving because the general risk for suicide in people
with schizophrenia is higher following an acute psychotic episode. It is estimated that
between 20% and 50% of patients with schizophrenia attempt suicide (Simon, 2002) and
one of every 10 people with schizophrenia eventually commits suicide (NIMH, 1999b).
Poor Concordance Rates
Terminology is an issue of historical and ideological scope directly influencing
the foundation for concordance interventions. Use of the terms, non-compliance or non
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adherence implies a paternalistic approach to health care (Gray, Wykes, & Goumay,
2002), casting the service user in the role of disobedient child. Consequently, it is
proposed that use of the word concordance, which emphasizes client rights, the need for
information, the importance of two-way communication and decision-making, supplant
the use of the word compliance (Gray, Wykes, & Goumay). The historical compliance
model is at odds with a new concordance model and the new ethics of modem mental
health care. Development and research is encouraged to base all interventions addressing
use of medications and treatment strongly in a concept of concordance. However, much
of the literature in this area utilizes the terms of compliance and adherence and provides
the foundation for this concordance concept.
The great economic and personal costs associated with poor concordance and
relapses have been the subjects of many studies. It is estimated that within two years of
beginning antipsychotic medication, 75% of individuals will stop taking them (Weiden,
& Olfson, 1995). Cramer and Rosenheck (1998) studied medication compliance rates and
determined average compliance with antipsychotic medications to be 58%, antidepressant
medications at 65%, and medications for physical disorders at 76%. When individuals
fail to take medication as prescribed, either stopping the medicine or taking it
sporadically, positive and negative symptoms return, psychosis and difficulty with reality
orientation reemerge. Relapse and costly hospitalization is associated with poor
concordance and is well supported in the literature (Brekke et ah, 2001; Oehl et ah, 2000;
PORT, 1998).
Poor compliance is described as when medication is not taken according to a
prescribed regimen (PORT, 1998); however, measures of the concept of compliance are
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inexact, thus making comparisons between interventions difficult. Difficulties in
measuring compliance may be one explanation for the inconsistencies in reported noncompliance rates for people with schizophrenia. Compliance assessment strategies range
from clinician determination, electronic pill bottle cap monitoring, to user self-report
scales, and interviews (Gray, Wykes, & Goumay, 2002).
The World Health Organization proposes that higher rates of treatment adherence
across all chronic disease categories would result in economic benefits by reducing health
care costs for illness exacerbations and boosting indirect benefits of improved quality of
life and increased social contributions (2003). The World Health Organization also
emphasizes that the concept of adherence is a multidimensional phenomenon requiring
interventions tailored to the particular needs of each patient.
Variables Associated with Poor Concordance
In a study to evaluate possible factors contributing to what they termed
medication non-compliance in schizophrenia, Agarwal et al. (1998) surveyed 78 patients
with schizophrenia using standardized instruments to measure Insight and subjective
response to medication; their families were administered a structured, Knowledge About
Schizophrenia interview. Results indicated that people with an episodic course of
schizophrenia, with onset of illness at 26 years of age and no side effects were 130 times
more likely to be non-compliant than compliant. Sixty-six percent of this sample under
the age of thirty was non-compliant with prescribed medication regimens (Agarwal et
at).
Hudson et al. (2004) completed a pilot study examining barriers to medication
adherence involving 153 patients with schizophrenia receiving inpatient and outpatient
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services at three Veterans Administration Medical Centers in the U.S. Nurse coordinators
at all three sites conducted a clinical interview lasting 20 to 60 minutes, focused on
evaluating barriers to medication adherence (Hudson et ah, 2004). The most commonly
reported barriers were stigma, adverse drug reactions, memory problems, and lack of
social support. Strategies to address each of these variables would include: (a) social
change to decrease stigma of mental illness, and increase community supports; (b)
improved practitioner-patient relationships; and (c) individualized, cognitively based
interventions to address practical issues. While this study focused on barriers to
treatment, other studies endeavored to identify factors that contribute to concordance.
Agarwal et al. (1998) identified several factors exerting a positive influence on
medication compliance for individuals with schizophrenia. Insight, which is defined as
the ability to recognize symptoms that arise from mental illness (David, 1990), was
associated with better concordance. This investigation also found an association between
positive attitude and knowledge about medication and increased levels of compliance
(Agarwal et ah). Oehl et ah (2000) determined treatment related issues such as physicianpatient relationship, expectations of the medication, and simple versus complicated
regimens to be important factors in their review of the scientific literature.
Idiosyncratic issues of concordance were addressed in Awad, Voruganti,
Heslegrave, & Hogan’s (1996) study of the subjective experience of antipsychotic
treatment. The authors noted that it is necessary “to accept the assumption that how
patients feel and function can contribute to a large degree to their compliance with
medications” (p. 57). Discerning relevant variables from the vast amount of literature on
concordance in schizophrenia repeatedly leads to the concept: decision making about
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treatment concordance is multifaceted. In a review of the literature covering 27 studies
addressing treatment concordance, Gray, Wykes, and Goumay (2002) differentiated 13
factors that emerged as influencing concordance.
Factors linked with service users being less likely to take medication as prescribed
include:
1) Presence of side effects.
2) Negative beliefs about treatment.
3) Poor symptom control.
4) Complex medication regimen.
5) Substance Abuse.
6) Impaired judgment.
7) Poor worker-service user relationship.
8) Poor communication
Factors linked with service users being more likely to take medications as
prescribed include:
1) Acceptance of illness.
2) A perception of severity or susceptibility
3) Level of support.
4) Family stability.
5) Positive therapeutic alliance.
6) Route of administration. (Gray, Wykes, & Goumay, 2003, p. 2).
Hughes et al. (2002) indirectly addressed these factors in a longitudinal study
involving 62 patients, determining that clinical treatment of cognitive impairment is an
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important aspect influencing treatment concordance. The authors recommended that
cognitive impairments be considered and treated separately from other symptoms
targeted with antipsychotic medications (Hughes et al.). Cognitive impairment seems to
directly affect medication concordance, when considering its profound influence on
judgment, relationships, complexity of medication regimens, beliefs, and communication.
(Gray, Rofial, Allen, Newy, & Gournay, 2003). Interventions that address these
components will address the many variables associated with concordance and will be
grounded in evidence-based concepts.
Interventions to Enhance Concordance
All interventions implemented in an effort to increase medication concordance
meet with varying degrees of success. Sensky et al. (2000) found in a study of cognitivebehavioral therapy (CBT) for treatment of persistent symptoms in schizophrenia, that
negative symptoms could be significantly reduced after an intervention of CBT.
Importantly, the efficacy of this talk therapy intervention on the reduction of negative
symptoms persisted for 9 months (Sensky et al.).
In a study targeting education as a means to enhance what they termed medication
compliance, Macpherson, Jerrom, & Hughes (1996) found that education alone led to
increased insight, but no change in compliance. The educational intervention under study
was structured, individualized and comprised of three educational sessions that resulted
In durable gains in insight. The authors found in this study involving 64 patients, that
education could engage individuals and improve acceptance and integration of the illness
(Macpherson et al.). This study, although aimed at an important variable associated with
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non-compliance, supports the concept that there is a need to address variables other than
education and insight concurrently.
In a meta-analysis of interventions to reduce treatment non-adherence, Nose,
Barbui, Gray, & Tansella (2003) systematically reviewed 23 studies involving over 3,500
subjects for evidence of effective community-based interventions. Literature from 1980
through 1998 was evaluated, ranging in concept from educational programs to telephone
prompts. The subgroup analysis revealed that all categories of interventions were
effective in lowering non-adherence rates. The authors concluded that while generalizing
was not recommended and no intervention emerged as predictive of a positive treatment
effect; there is strong, scientific evidence that community interventions can effectively
influence treatment adherence. (Nose et al.).
Compliance Therapy, Adherence Therapy
A randomized controlled trial of an intervention of compliance therapy, devised
by Kemp et al. (1996) involved 74 service users with schizophrenia in the United
Kingdom (UK). In this study, compliance therapy is described as involving cognitive
behavioral techniques and motivational interviewing with a more active therapeutic
stance. The intervention led to sustained improvements in compliance rates at a six month
follow-up. Important outcomes of this study at the 18-month follow-up included a
significant decrease in the number of relapses, an increase in Insight, compliance, and
global functioning, for the intervention group compared to the control group. Importantly,
Kemp et al. notes that an expected concomitant reduction in positive symptoms did not
occur. One clinical implication cited in the 1996 study was to examine the possibility of
teaching the technique to a range of health professionals (Kemp et al., 1996).
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Summarizing a research review of numerous interventions, Gray, David et al.,
(2003) concluded that effective interventions focusing on concordance would consist of
five evidence-based elements.
1. Consistent use of a collaborative approach to working with service users.
2. Giving service users information about their illness and treatment.
3. Encouragement of tailoring medication regimens to suit the user.
4. Consistent use of motivational interviewing and cognitive behavioural
techniques.
5. Careful assessment of service users’ beliefs and experience of treatment with
antipsychotic medication (p. 2).
These five critical elements were incorporated into a medication management-training
package that was delivered to community mental health nurses (CMHN) in the U.K. A
randomized controlled trial (RCT) was conducted to assess the effects of the medication
management package on the CMHN’s skills and on the clients’ clinical outcomes. This
trial demonstrated: (a) training effectiveness, (b) user satisfaction of both clients and
clinicians, (c) improvement in attitudes towards treatment, (d) increased medication
compliance and (e) a reduction of symptoms for clients in the medication management
group, as compared to the treatment as usual group. Variable measures included (a)
severity of symptoms in schizophrenia using the Positive and Negative Syndrome Scale
(PANSS) and (b) changes in attitude toward medication and (c) treatment using the
Hogan, Drug Attitude Inventory (Hogan, Awad, & Eastwood, 1983). Clinician-ratings of
compliance were also used to assess compliance, change in insight and side effects (Gray,
Wykes, Edmonds, Dickson, Leese, & Goumay, 2002),
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Following this study, Gray, Goumay, and David (on behalf of the European
Quatro research group) developed a training manual to further implement Quatro
Adherence Therapy. Quatro Adherence Therapy is a brief, structured medication
management therapy for users of psychiatric services with schizophrenia. Adherence
therapy is characterized by its use of motivational interviewing and cognitive behavioral
therapy techniques to focus on involving service users with schizophrenia and
schizoaffective disorders in treatment decisions, and discussing their concerns (Gray,
David et ah, 2003). Completion of QAT is associated with an increase in treatment
concordance, and a reduction of symptomatology for service users. This individual
therapy focuses on the needs, concerns, fears, values, goals and experiences of the
individual with the aim of encouraging people to take their medications. There is an
urgent need to integrate these practices throughout the mental health care system (Gray,
Wykes, & Goumay, 2002; Kemp et al., 1996).
One recent study stands in contrast to the success of the Quatro Research Group’s
efforts. O’Donnell et al.’s (2003) study sought to establish the efficacy of compliance
therapy among patients with schizophrenia. Fifty-six patients admitted to an inpatient
psychiatric unit with psychosis were randomized to receive compliance therapy or non
specific counseling. The main outcome measures were: compliance with drug therapy at
one year, attitudes towards medication, insight, symptomatology, overall functioning,
quality of life at one year, and occupancy of psychiatric hospital beds for two years. The
authors note outcomes for the study indicated that compliance therapy imparted no
advantage over non-specific therapy for any of the main outcome measures. One
important limitation of the study was the small sample size, which was insufficient to
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detect statistical significance. Importantly, this study did not report how fidelity to
compliance therapy was monitored or if a determination was made that compliance
therapy was provided in accordance with established protocol.
The European Commission is currently funding a four-country randomized
controlled trial to study the effectiveness and costs of adherence therapy for people with
schizophrenia (European Union, Action Line: Quality of Life-2000). This major
undertaking called “Quatro” is currently in progress in London, England; Verona, Italy;
Leipzig, Germany; and Amsterdam, Netherlands (Gray, David et al., 2003). The Quatro
research group represents a collaborating effort of European researchers coordinated by
King’s College London to investigate and develop treatment interventions for
schizophrenia (D. Robson, personal communication May 30, 2004). Effective
management of schizophrenia appears to incorporate a user-centered evaluation of
pharmacological interventions; uncomplicated information and the use of both
motivational interviewing and cognitive behavioral techniques to help service users make
educated decisions about their treatment. There is evidence that routinely incorporating
these concepts into the fundamentals of mental health care improves service users’
mental health (Gray, & Odunlade, 2002).
Gaps in the Research Literature
There appears to be very little research in the United States of Interventions
designed to improve concordance for people with schizophrenia. An electronic search of
ClinicalTrials.gov, an internet database that provides information about federally and
privately supported clinical research in the U.S., reveals 65 studies currently registered
for treatment of schizophrenia (National Institute of Health, 2003). Of these 65 studies,

34

one specifically addresses medication adherence. This study, which has not yet begun,
will evaluate the effectiveness of a practical, pharmacy-based intervention for improving
adherence among clients with schizophrenia.
The Surgeon General’s report on mental health addressed pronounced gaps in the
mental health knowledge base and defined an urgent need for, evidence which supports
strategies for mental health promotion and illness prevention. The report concluded
further that an abundance of new medications and treatments for mental disorders
challenge the scientific community to develop new methods to deliver health care
services (NIMH, 1999a, p. 21).
Final recommendations from this report include the following admonition:
Ensure Delivery of State-of-the-Art Treatments’. A wide variety of effective,
community-based services, carefully refined through years of research, exist for
even the most severe mental illnesses yet are not being translated into community
settings. Numerous explanations for the gap between what is known from
research and what is practiced beg innovative strategies to bridge [the gap] it
(NIMH, p. 22).
Finally, previous studies of QAT have been completed with CMHNs as therapists. To,
date no studies have been done using mental health therapists of other disciplines such as
clinical social work, marriage and family therapists and licensed mental health
counselors.
Summary
Literature regarding the significant impact of schizophrenia on life processes
spans the concepts of neurobiological theories, global burden, intrinsic worth, and human
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nature. It is clear from a review of the literature that serious economic and personal
burdens for individuals with this illness and their families can be positively impacted.
Beginning with pharmacological interventions in the 1950s, treatments for severe mental
illness have increasingly relied on the methods of scientific inquiry for improvements in
efficacy.
The variables contributing to treatment outcomes for people with schizophrenia
have been studied, and used as the basis for developing new therapeutic interventions.
Medications, when taken as prescribed, effectively reduce the symptoms of schizophrenia
for many individuals and lead to better outcomes in life functioning. Yet, making
decisions to take or not take medication as it is prescribed “seems to be entrenched in
human nature and perhaps should be viewed as normal behavior” (Gray, David et al.,
2003, p. 2). Describing medication-taking behavior as abnormal is demeaning and
possibly furthers the negative stigma for those with metal illness. Especially with regard
to the very similar rates of poor treatment concordance seen in virtually all chronic
illnesses (Gray, David et al.). Based in a concordance framework, decision making about
taking medications revolves around numerous variables with an overriding influence of
ambivalence.
Results of recent studies of an intervention for adherence therapy indicate that a
process of collaboration, information sharing, value exploration, and review leads to
improved outcomes for people with schizophrenia. Based on the theories of motivational
interviewing and cognitive behavioral therapy, it is reasonable to believe that through the
QAT intervention, a cognitive shift takes place, helping individuals modify their
medication taking decisions. Improved treatments for schizophrenia need to be developed
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through research to determine the effectiveness of interventions and increase
understanding of the outcomes of interventions on the illness. The literature review
supports the need for research that demonstrates the influence of QAT and its methods on
changes in symptomatology and concordance with medication regimens.
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Chapter III

Methodology
Introduction
This pilot study was conducted as partial requirement toward the degree of Master
of Science in Nursing. In this chapter, the overall plan of the pilot study is detailed; the
study design, site, participants, and procedures are described. Further, an explanation of
the intervention, training, and monitoring of the pilot study is provided. Finally, a
discussion and description of the data collection involved in measuring study variables
and the procedures for protection of human subjects are included.
Pilot Study Design
A randomized, experimental pilot study design was developed to test if there was
a difference in the severity of symptomatology of schizophrenia or medication
concordance for individual participants who participated in an intervention of QAT. The
intervention was added to the service user’s usual treatment.
Site
Archways Behavioral Health Care Center (Archways) in Fort Lauderdale, Florida
is a not-for-profit community mental health center (CMHC) and is the only site at which
the research was conducted. This agency has a stated mission (see Appendix B for copy
of Archway’s Mission Statement) to “provide quality comprehensive behavioral health
care to individuals and families who are in need of improving their quality of life”
(Archway’s Mission Statement, 1995). The agency, a member of Florida Council for
Community Mental Health, has been in operation for over twenty years, and is a provider
of services for Broward County Community Mental Health Services Division
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(BCCMHSD). The State Department of Children and Families, Alcohol, Drug Abuse and
Mental Health Program, through its contracts with BCCMHSD, is the main provider of
mental health services in Broward County and maintains contracts with local providers
for services.
Archways’ mental health services include community mental health day
treatment, several levels of residential community living services, case management,
medication management, employment placement, individual counseling, and psychiatric
evaluation services. The therapists involved in this pilot study are on staff at Archways,
and provide ongoing therapy to clients at Archways. Archways provides a range of
mental health services to approximately 425 service users living in Broward County,
Florida.
The Chief Executive Officer (CEO) of Archways and the Board of Directors of
Archways agreed to participate in the pilot study by offering service users the opportunity
to participate in the intervention under study and documented this decision with a letter of
support and agreement (see Appendix C for copy of the CEO’s letter of support and
agreement). The principal investigator received formal approval for this pilot study from
the Florida International University, Institutional Review Board (IRB), on March 25,
2004 (see Appendix D for copy of IRB confirmation of approval to conduct research).
Case managers, advanced registered nurse practitioners, and psychiatrists practicing at
this site were informed and educated with regard to the aims of this pilot study and the
implications for their practice, prior to its start.
To conduct this pilot study, the Chief Executive Officer of Archways directed the
principal investigator to accept active volunteer status. This allowed the principal
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investigator access to participants5 records and the agency database in accordance with
agency confidentiality protocol (see Appendix E for copy of Volunteer Confidentiality
Agreement). The principal investigator was an employee of Archways for 8-years and is
currently in a clinical preceptorship with a treating psychiatrist at this agency. The agency
plans to implement the intervention of QAT on a regular basis after the completion of the
pilot study.
Sample
One hundred thirty adult, male and female participants, with a current diagnosis
of schizophrenia or schizoaffective disorder who were receiving psychiatric case
management services from Archways, were approached for inclusion in the pilot study.
The sample recruited was 24 participants, 10 in the experimental (QAT) group, and 14 in
the comparison, treatment-as-usual (TAU) group, for this pilot study. Participants’ ages
ranged from 21 to 61, with 79% male and 21% female. The population ages ranged from
18 to 61, with 65% male and 35% female service users.
To achieve a power level of .80, 120 participants, with approximately 60 per
group were needed. Because the resources available for the pilot study limited the total to
24 service users, the pilot study is obviously underpowered. However, completion of this
pilot study will enable an estimate of effect sizes in our replication of the technique in
South Florida, and thereby set the empirical basis for the funding of a larger study in
South Florida.
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Eligibility Criteria
Inclusion criteria for participants:
1. Current recipient of services from Archways Behavioral Health Care
Center.
2. Diagnosis of schizophrenia or schizoaffective disorder utilizing the
current DSM-IV-TR criteria.
3. Recommendation from mental health care provider for participants’
inclusion in pilot study.
4. Male or female adult (over 18 years of age) willing to participate in
pilot study and able to give informed consent.
5. Currently prescribed medication for treatment of schizophrenia or
schizoaffective disorder.
6. Able to read and understand English language.
Exclusion criteria for participants:
1. Co-morbid Axis I diagnosis of moderate or severe learning disabilities
or organic brain disorders.
2. Co-morbid Axis I diagnosis of substance abuse/dependence disorder,
unless specified in remission.
3. Inpatient status at start of the pilot study.
4. Suicidal or homicidal ideation assessed at start of pilot study.
5. Children under the age of 18 are excluded from the pilot study.
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Procedures
Clinician training. Dr. Richard Gray, RN, PhD, and Deborah Robson, RN, BSc,
developers of the QAT program in the United Kingdom (U.K.), conducted clinician
training. Individuals who received this training include: the QAT pilot study therapists,
the principal investigator, the principal investigator’s major professor, and the on-site
research assistant, who assisted with randomization and on-site coordination/logistics.
Training was conducted at Archways’ conference room in accordance with the
manualized training program, from February 23 through February 25, 2004, and covered
the techniques and principles of QAT. The training was offered at no cost to the
participants.
The QAT pilot study therapists currently provide individual counseling at
Archways. One therapist has been employed by this agency for over nine years and is a
licensed clinical social worker. Another therapist has been employed by this agency for
four years and is a master’s prepared, licensed mental health counselor. The third
therapist has been employed by the agency for two and one half years and is a master’s
prepared registered marriage and family therapy intern, who recently completed two
years of required supervision and is eligible to sit for licensure.
Recruitment. The referral source for recruitment of participants was Archways
Behavioral Health Care Center in Fort Lauderdale, Florida. Participants were current
clients receiving outpatient psychiatric healthcare services at the time of this pilot study.
The principal investigator Identified potential participants by virtue of their DSM-IV,
Axis I diagnosis accessed through Archways’ database. Addresses for potential
participants were then extracted from this database. A letter inviting participation in QAT
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therapy as part of a research project was mailed to all eligible participants (see Appendix
F for copy of the invitation to participate letter). A postcard reply form was included with
the letter requesting a response (see Appendix G for copy of postcard reply).
Potential participants were instructed via the invitation letter to drop off the
postcard reply form, after having indicated on the reply card either, (a) interest in being
contacted or (b) no interest in the study. A closed box was positioned in an easily
accessible location behind the desk in the reception area of Archways for receipt of the
reply cards. During the week following the mailing of the invitation letter, the principal
investigator and the onsite research assistant made in person, follow-up contact at the site
to both the potential participants who returned the reply card indicating interest and the
non-responders. The principal investigator and onsite research assistant approached
potential participants, personally at the clinic site through arrangements made with their
case manager or day treatment advisors (see Appendix H for scripting of the follow-up
contact).
During the second week following the mailing of the invitation, the principal
investigator remained onsite for several hours, on several days to be available for
approach from potential participants. Concurrently, during this second week, Archways’
residential director and the day-treatment supervisor notified potential participants of the
principal investigator’s availability. Potential participants then met with the principal
investigator at the clinic site. Once participants agreed to participate, informed consent
was obtained (see Appendix I for copy of Informed Consent) and appointments were
scheduled for baseline assessments.
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All participants received scripted verbal instructions and understanding was
confirmed before participants’ completion of the self-administered instruments. The
principal investigator and the designated offsite research assistant completed the baseline
SCI-PANSS assessments for all pilot study participants who signed informed consent. At
the same interview, each study participant completed the PETiT, a self-scored scale. Both
the principal investigator and the offsite research assistant were blind to the comparison
or experimental status of the participant.
The onsite research assistant using random table assignment assigned the twentysix participants who signed an informed consent into either the TAU group of 14
participants, who continued to receive treatment as usual or the QAT group of 12
participants who received the intervention. The onsite research assistant, who alone knew
the participants’ names and associated identification numbers, and completed this
procedure, assigned each participant an ordinal pilot study identification number. Then,
the onsite research assistant used the JavaScript random number generator program,
Research Randomizer (Houle, 1997-2003) available at http://www.randomizer. org/ to
produce customized sets of random numbers. Each participant was then assigned to either
the QAT or TAU group. The current version of Research Randomizer, v3.0random table,
uses the Math.random method within the JavaScript programming language to generate
its random numbers (Houle). This program generates random number tables by use of a
complex algorithm seeded by the computer's clock (Houle).
Once random assignment was completed, participants in both study groups were
notified of their status. The onsite research assistant notified participants assigned to the
TAU group of their status. Comparison participants were reminded to not discuss their
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study status with either the principal investigator or the offsite research assistant. Either
the onsite research assistant contacted participants assigned to the QAT group or their
pilot study therapist and individual appointments were scheduled among the three
therapists. QAT therapists contacted experimental participants directly in order to
schedule appointments. Experimental participants then participated in 1 - 2 sessions of
QAT per week. The onsite research assistant maintained contact with the TAU group of
participants through casual contact during her working hours at Archways. The onsite
research assistant works full time at Archways in the day treatment program. In the
course of a typical working day, she has casual contact with most day treatment clients,
which included comparison and experimental participants.
Data collection.
Data were collected at baseline, before the introduction of the intervention, and at
follow-up, after completion of the intervention. At baseline, demographic information for
all participants was extracted from the medical chart to include: gender, age, date of birth,
ethnicity, years of education, number of psychiatric hospitalizations, and residential
situation (see Appendix J for Demographics Information Collection Form). Demographic
information was collected to establish a basis for comparison between the TAU and QAT
groups and to analyze for significance of group differences.
Measures
Two major instruments, the Structured Clinical Interview Positive and negative
syndrome scale (SCI-PANSS) and the Personal Evaluation of Transitions in Treatment
(PETiT), were completed at baseline and follow-up. These two instruments were used to
measure the dependent variables in this pilot study, severity of symptomatology and
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medication concordance respectively. Further, the Schedule for the Assessment ofInsight
- Expanded (SAI-E), and the Liverpool University Neuroleptic Side-Effect Rating Scale
(LUNSERS) were used to monitor participants’ participation in the intervention and to
provide QAT therapists with a formal means of obtaining information pertinent to the
participants’ experiences with psychiatric medications
Positive and Negative Symptom Syndrome Scale (PANSS). The PANSS is a scale
measuring the positive and negative symptom syndromes experienced by individuals with
schizophrenia (Kay, Opler, & Lindenmayer, 1989). A Structured Clinical Interview
component can be used with the PANSS, called the SCI-PANSS that provides
interviewers with increased consistency. The publishers and authors of this instrument
report that the SCI component, a series of questions, increases inter-rater reliability and
optimizes the scale’s objectivity and standardization (Kay, Opler, & Fiszbein, with
Ramirez, & White, 2000) (see Appendix K for selected examples of SCI-PANSS).
The PANSS is a standardized measure of the presence of symptoms in
schizophrenia. It consists of 30-symptom items that are rated on a 7-point Likert scale,
with 1 being equal to the absence of a symptom and 7 being equal to extreme interference
of a symptom. Kay et al. (1989) reports the PANSS yields four syndrome scores
{positive, negative, composite and general psychopathology) and five cluster scores
(anergia, thought disturbance, activation, paranoid belligerence and depression).
Higher scores on PANSS subscales reflect a greater severity of symptomatology.
The range of possible scores for the PANSS positive and negative subscales is from 7 49. The PANSS positive subscale is comprised of scores for the presence and severity of
seven symptom identifiers: delusions, conceptual disorganization, hallucinatory behavior,
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excitement, grandiosity, hostility and suspiciousness/persecution. The PANSS negative
subscale is also comprised of scores for the presence and severity of seven symptom
identifiers: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social
withdrawal, difficulty in abstract thinking, lack of spontaneity, stereotyped thinking and
flow of conversation. The range of possible scores for the PANSS general
psychopathology subscale is from 16-112. The PANSS general psychopathology
subscale is comprised of 16 symptom identifiers: somatic concerns, anxiety, guilt
feelings, tension, mannerisms and posturing, depression, motor retardation,
uncooperativeness, unusual thought content, disorientation, poor attention, disturbance of
volition, lack of judgment and insight, poor impulse control, preoccupation, and active
social avoidance (Kay, & Fiszbein, with Ramirez, & White, 2000).
Scores in the initial standardization studies indicate a moderately high internal
reliability with Cronbach’s alpha coefficients ranging from, a = 0.73 to a = 0.83 withp
< .001 (Kay et al., 2000). Studies have demonstrated confirmation of this instrument’s
good construct validity for mutually exclusive symptom dimensions (Kay et al.). The
SCI-PANSS is used clinically and has been used in numerous studies to evaluate the
severity of symptomatology in schizophrenia and its relationship with an intervention to
reduce symptomatology (Gray, Robson, & Bressington, 2002; Gray, Wykes, Edmonds et
al. 2002; Hughes et al., 2002; Rector, Seeman, & Segal, 2002). Additionally, the PANSS
or SCI-PANSS is routinely used in clinical trials of neuroleptic medications to evaluate
symptom reduction related to the use of medications (Oehl et al, 2000; PORT 1998).
Personal Evaluation of Transitions in Treatment Scale. The PETiT was
developed to assess the subjective evaluation of an individual’s experience with treatment
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for schizophrenia (Voruganti, & Awad, 2002). This instrument is a 30-item, self-rated,
scale with each item receiving a rating scale of (a) always, (b) sometimes, and (never).
These scales are converted to scores with 0 = negative response, 1 = sometimes, and 2 = a
positive response. The scale labels always and never and their corresponding values vary
according to the wording of the question. Comparatively higher scores indicate a higher
satisfaction with treatment and medication compliance. The score considers subjective
aspects of psychosocial functioning and quality of life including medication compliance
specific questions (Voruganti, & Awad). The scale is perceived as user-friendly by
subjects and can be completed in approximately 3-8 minutes. Voruganti, and Awad
reported high internal consistency, with a Chronbach’s alpha oc = 0.96 and good split-half
reliability (see Appendix L for copy of PETiT).
At the suggestion of Dr. Richard Gray, this tool was recommended to capture the
participants’ medication concordance based on the item composition (R. Gray, personal
communication December 12, 2003). Voruganti and Awad indicate that this scale should
be very useful in intervention research for individuals with schizophrenia (2002). Further
Voruganti and Awad suggest in the scales instructions for use, that the last six items of
the scale can be used as a subscale to assess medication concordance. PETIT was recently
developed and validated in 2002 and as a result no other published studies were found
that used this measure for research outcomes. Several researchers have requested to use
this scale; so further information regarding the usefulness of this scale should be
forthcoming in the literature (Kathryn McColl, personal communication January 26,
2004).
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Schedule for Assessment ofInsight. The SAI-E is a measurement tool completed
by the clinician formulated to assess an individual’s level of insight in to diagnosis,
awareness and understanding of symptoms (David, 1990). Components of this instrument
measure treatment compliance, awareness of illness and ability to re-label psychotic
symptoms correctly (Kemp, & David 1995). Research regarding the scale reveals a
Cronbach’s alpha, a = 0.92 (Sanz, Constable, Lopez-Ibor, Kemp, & David, 1998). SAI-E
is useful in assessing relevant treatment and patient related variables with regard to the
subject’s abilities, willingness, and understanding of mental illness and treatment (Kemp,
& Lambert, 1995). This scale was used to provide QAT therapists with a consistent and
formal procedure for assessing participants’ insight, and no outcome data will be
analyzed from this scale (see Appendix M for copy of the SAI-E).
Liverpool University Neuroleptic Side-Effect Rating Scale. (LUNSERS). This
instrument is a self-rated, 41-item scale, which measures the frequency of medication
side effects (Day, Wood, Dewey, & Bentall, 1995). Day, et al. reports the test-retest
reliability of the LUNSERS is satisfactory (r = 0.811, and p <0.001) (1995). For this
scale, service users self rated their experiences choosing from a continuum of 5 responses
ranging from Not at all to Very much. The QAT pilot study therapists used this
assessment tool for evaluating presence and impact of side effects. The LUNSERS covers
known psychological, neurological, autonomic, hormonal and miscellaneous side effects
(Morrison et al., 2000). In addition, this scale contains 10-red herring items, which assist
researchers in identifying individuals who might tend to either over-estimate or have
cognitive difficulties, impeding their ability to recognize side effects (Morrison et al.).
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Studies of the effects of a CBT intervention (Sensky et al., 2000), a medication
management intervention by Gray, Robson, & Bressington, (2002) and a study of an
education intervention (Macpherson et al., 1996) each used the SAI-E and the LUNSERS
to evaluate outcomes and relationships between the variables of side effects and insight in
their interventional studies (see Appendix N for copy of the LUNSERS). After the
baseline data was collected, the QAT intervention was introduced to the experimental
participants.
Explanation ofIntervention
Quatro Adherence therapy is a structured pragmatic intervention based broadly on
the techniques of motivational interviewing and cognitive behavioral therapy (Gray,
Goumay, David et al., 2001, p. 13). The process of this intervention, involves the
therapist working to develop discrepancy and importance as two key concepts in
resolving ambivalence (Gray, Goumay, David et at).
Before the start of therapy, therapists considered the physical environment,
privacy, shared access with participants to notes taken and style of dress (Gray, David,
Goumay et al., 2001). The physical environment was private and comfortable for both
therapist and participant and style of dress was casual and modest. Furniture was
arranged so that both therapist and participant had access to a common writing surface.
Adjustments were made to encourage rapport building.
Goals, Principles and Overriding Themes
Therapeutic guidelines required the therapist to follow participant responses
carefully (Gray, Goumay, David et al., 2001). Participants were made aware that the
therapist would be listening carefully in order to develop an understanding of the

50

participant’s viewpoint. Attentive listening on the part of the QAT therapist was crucial
to picking up the threads of positive statements in the client’s narrative.
The therapy had three phases, followed by an evaluation, and usually spans eight
individual sessions for completion. Quatro Adherence Therapy embraces social learning
theory, which explains that as social beings, humans talk themselves into what they
believe. Peplau’s theory of the nurse-patient relationship also stresses that conscientious
listening on the part of the nurse allows the patient to develop a narrative within which
changes in self-view can develop. QAT pilot study therapists in at least two ways applied
this theory, (a) clients were specifically asked to describe the good things about
medication and treatment, and (b) clients were asked to elaborate when they verbalized
positive change statements (Gray, David et al., 2003). There were several key principles
overriding each session. These principles require the therapist to:
1)

Take an active therapeutic stance during the course of therapy.

2)

Emphasize personal choice and responsibility.

3)

Facilitate the building of self-esteem in the client.

4)

Encourage identify and support self-efficacy for the client.

5)

Maintain a flexible, neutral and safe environment.

These principles were applied in therapy by the use of specific counseling
techniques required of the therapist. These techniques were learned by the therapist
through formal education in a master’s program of study and refined through years of
clinical supervision.
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Required counseling techniques include:
1)

Collaborative agenda setting

2)

Feedback and understanding

3)

Reflective listening

4)

Collaboration

5)

Pacing and efficient use of time

6)

Developing discrepancy

7)

Dealing with resistance

Each session began with a concern check and agenda setting. This was important
for immediate concerns or problems of the participants to be addressed at the start of each
session. This allowed both therapist and participant to focus on the goals of adherence
therapy for the remainder of each session.
Fidelity to these therapeutic techniques was critical to maintaining the integrity of
the intervention, as progress was made through each phase of therapy. The initial phase
termed, engagement phase, was typically completed in the first session. The second,
assessment phase was completed in one to two sessions and guided by an assessment
form. The third phase consisted of five to six sessions, comprising the therapeutic phase.
After the completion of the third phase an evaluation was conducted, and concluded,
usually in one session.
Quatro Adherence Therapy Interventions
In the initial session, therapists engaged in conversation with the participant,
establishing rapport. This was done through a focused discussion regarding the
participant’s views of taking medication. Acceptance of participant views, genuine
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interest, feedback of understanding and a conversational style were crucial to the
engagement phase. Expectations and clarification of the process were provided to the
participant at each session. The assessment phase was structured according to an
assessment form. This form was completed as a collaborative effort and the participant
was given a copy of the summary at the completion of the assessment phase. Focus in the
assessment phase was on eliciting participant’s views about medication and thoughts
about current and previous treatment. Although engagement was considered complete
after the initial session, a need for a return to engagement strategies was assessed as
therapy progressed.
Information gathered in the assessment phase provided a basis for discussion
during the therapeutic phase. The therapeutic phase was managed with the use of discreet
interventions, of which five were mandatory, and six were discretionary. Each
intervention was designed to address importance, confidence or both of these concepts as
they related to the participant’s medication/treatment adherence (Gray, David, Goumay et
al., 2001). These discreet interventions or exercises were delineated in the QAT training
session; several employed simple pencil-and-paper forms to assist in clarification and
fidelity to the therapeutic process.
At the completion of the therapeutic phase, a last session was scheduled to
conduct an evaluation. The evaluation phase, one session, was essentially a repeat of the
assessment phase conducted in an informal, conversational, and collaborative manner
(Gray, David et al., 2003). The goal was to review the course of the illness and consider
the progress made throughout therapy. It is especially helpful to clarify how ambivalence
may have been resolved over the course of therapy.
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Mandatory interventions. These interventions are required to be delivered within
the course of the therapeutic phase of QAT. All descriptions of mandatory interventions
were adapted from, Adherence Therapy Manual, Version IV, (Gray, David et al., 2003).
1)

Sorting Out Practical Issues1.This intervention addressed issues related to
obtaining medication or influencing the participants’ forgetting to take
medication. Practical solutions were generated for simple problems.

2)

Looking Back'. This intervention explored previous treatment experiences and
strategies that were helpful as well as those that were not helpful. Repeated
failures may diminish self-efficacy, so emphasis in this exercise was on
positive and helpful experiences. Therapists made detailed notes with the
client and worked logically through the experiences. Emphasis was made for
any links between stopping medication and relapse. Negative experiences
were not ignored.

3)

Exploring Ambivalence'. This exercise explored the variety of beliefs and
uncertainties about the importance of medication. Emphasis was on assisting
participant to explore their personal reasons for taking or not taking
medication. Dialogue was focused on the good and not so good things about
medication. Therapist provided structure, listening and summarizing.
Therapists did not argue whether to stop or to take medications, nor did they
tell clients the advantages or costs of taking or not taking medications.

4)

Discussing Beliefs and Concerns'. Summary of clients’ beliefs about illness
and treatment should have emerged by the time this intervention was
introduced. Beliefs were explored one by one, asking the client to talk about

54

evidence both for and against each belief. Clients were asked about different
thoughts and encouraged to think about evidence. Therapists summarized
regularly.
5)

Looking Forward: In this exercise, focus was on maintenance of change.
Identifying goals or targets that the participant identified and would like to
achieve. Potential barriers were addressed. A problem solving approach was
used to identify broad and specific goals. Therapists used this opportunity to
talk about the importance of maintaining health in order to achieve selfidentified goals. Therapists helped build confidence with summarizing
positive examples.
Discretionary interventions. These interventions are deployed at the discretion of

the QAT therapist based on their assessment of the client’s needs during the therapeutic
phase of QAT. Each discrete intervention addresses a specific issue that may be relevant
to an individual client’s situation. All descriptions of discretionary interventions were
adapted from, Adherence Therapy Manual, Version IV (Gray, David et al., 2003).
1)

Examining Negative Treatment Experiences’. Clients with unpleasant
memories of being restrained or given an intra-muscular injection of
medication were invited to share and have these experiences acknowledged.
Clients were also encouraged to be more involved and take control of
treatment decisions.

2)

Identifying the Less Obvious Benefits ofMedication: If clients failed to see a
link between medication and symptom reduction, less obvious benefits were
explored carefully. Time was spent exploring alternative benefits such as
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fewer fights, getting on better with family, and staying out of the hospital.
Offers to spend time talking about less obvious effects of taking medication
were made. Everyday things that are easier to do or how other people react or
what other people may say about them when the client is taking medication
were explored. Clients were not told how much better they are when on
medication.
3)

Target Symptoms'. The therapist assisted the client to identify which
symptoms or feelings they would like to target. Some clients say they feel
more relaxed or can think better. The clients’ own words and symptoms were
rated on a severity scale over time and used to monitor change in target
symptoms. Monitoring may help provide a link between medication and
benefits, but this was for the client to describe and monitor, not the therapist.

4)

Normalizing Rationales'. Some clients tend to think of medication as a cure,
like antibiotics, time-limited and not needed once theyfeel better. Clients
were helped to reframe the illness as one that requires maintenance treatment.
The vulnerability-stress model was explained in detail. The therapist helped
the client to look back over experiences of treatment and make the link
between increased susceptibility to stress. Only if the client accepted
rationale were analogies made to other illnesses. Emphasis was made that
everybody has potential to get ill.

5)

How Things Would Be Different If...’. Therapists asked the client to think
hypothetically about stopping medication and then to think hypothetically
about continuing to take medication. The aim was to further explore the
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importance of taking medication. Therapist emphasis was on how things
would be different if......
6)

Medication Problem Solving: This exercise addressed problems clients have
with medication. Side effects, such as weight gain might have been
discussed. A problem solving strategy was used to address the problems. A
specific problem was chosen and agreed on as a target to achieve. Broad
steps needed to achieve the goal were outlined. Client decided on the details
of what the practical and realistic tasks necessary to achieve were, then
progress was reviewed. Achievable, realistic goals were chosen.

Offsite Monitoring
Monitoring of the intervention for fidelity involved recorded audiotapes of ten
randomly selected therapy sessions. All potential sessions were identified and assigned an
ordinal identification number. The process for selection of random sessions for taping
was the same process utilized for participant assignment as described earlier. Participants
were informed of the taping and had the opportunity to refuse the audio taping of the
session. Refusal to participate in audio taping of a session did not affect the participants’
involvement in the pilot study. A signed release was obtained from the participant and
therapist upon consent (see Appendix O for a copy of the Media Consent/Release Form
for audiotape).
One copy of each of the original audiotapes was made. The copies were sent to
Dr. Richard Gray, RN, PhD and Deborah Robson, RN, BSc for them to determine this
pilot study’s fidelity with established standards. This assessment was conducted using the
Therapist Fidelity Monitoring Protocol (Gray, & Robson, 2002) (see Appendix P for
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copy of Therapist Fidelity Monitoring Protocol), a recognized fidelity-monitoring tool
already in use in the U.K. to measure fidelity with training standards. This procedure will
allow future analysis and comparison of therapeutic standards between the U.K. and this
South Florida pilot study.
Onsite Monitoring
The principal investigator’s major professor, who also completed the adherence
therapy training, provided regular onsite supervision to the adherence therapists. She is an
Advanced Practice Nurse, and Licensed Marriage and Family Therapist with 20 years of
experience providing psychotherapy and case supervision, and 15 years experience
providing inpatient psychiatric services.
Quatro Adherence Therapy Program Satisfaction Questionnaire (QPSQ) (Ford,
& Anderson, 2004). The principal investigator and major professor developed this form
in order to gather information regarding user satisfaction with both the intervention and
the experience as a study participant. Information from this survey was analyzed to
determine how study participants perceived the intervention. Feedback regarding the pilot
study from participants Is potentially useful to modify future delivery and research of this
Intervention (see Appendix Q for copy of the QPSQ).
At the completion of the intervention, the onsite research assistant and the QAT
pilot study therapists organized scheduling of appointments with both the QAT group
participants and the TAU group participants for the follow-up assessments. The principal
investigator and off site research assistant completed all follow-up assessments. The TAU
group was scheduled to receive QAT after the follow-up assessments were completed.
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Data Analysis
Statistical analysis included univariate /-tests to examine the effect of the
intervention on the dependent variables of severity of symptomatology, measured by the
SCI-PANSS, and medication concordance, measured by PETiT. Mean baseline and
change scores allowed for comparison between groups. Mean and change scores were
then compared by group using independent sample t-tests. Additionally, follow up data
for all subscales were compared separately for each group using paired sample t-tests to
determine significant within group differences.
A MANOVA analysis examined change over time for each dependent variable.
Statistical analysis examined significance of differences between baseline and follow-up
measures of the dependent variables. Results of the statistical analysis of the SCIPANSS, and PETiT data and descriptive statistics (means, standard deviation and skew)
of the demographic data, are presented in the results section of this thesis. Test results
were considered significant for p < .05. Comparison of demographic variables for
significant differences between the experimental (QAT) and comparison (TAU) groups
was conducted using independent samples and paired sample /-tests (Polit, & Hungler,
1999), as well as Chi Square and crosstabulations to determine significance of variance at
baseline between the two groups.
Protection ofParticipants
This pilot study examined the differences between baseline and follow-up
measurements of concordance and severity of symptomatology scores. All individuals
who participated in the conduct of this pilot study have completed the required IRB
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training (see Appendix R for Human Participation Protections Certification for all study
participants).
Participants were expected to benefit from participation in this pilot study by
receiving individual counseling aimed at increasing their knowledge and awareness of
their diagnosed illness and medication regimen. A 20% improvement in psychopathology
or mean change score of .45 measured by the SCI-PANSS would represent meaningful
improvement (Cramer, Rosenheck, Henderson, Thomas, & Chamey, 2001). If as
anticipated, this intervention was found to be associated with positive results for the pilot
study participants, Archways plans to offer QAT to other individuals at the study site.
QAT is designed to minimize discomfort and therapist “scripting” addresses
emergent concerns or problems both before and after the completion of therapy sessions.
Therefore, other potential problems elicited from participants are not avoided or
disregarded in order to meet pilot study requirements. QAT therapists noted that no
emergent problems required addressing. Psychiatric and case management staff were
available through regular Archways policy, either in person or by phone, to address any
emergent crises. Therapists accommodated scheduling needs of participants as much as
possible.
The researcher was available at all times by cell phone to answer procedural
questions regarding the intervention. In addition, Dr. Gray and Ms. Robson were
available via email to respond to specific questions and provided co-clinical supervision
on one occasion with Dr. Anderson via telephone conference call.
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Alternative Treatments
All participants were free to consider and pursue alternative treatment, but none
was offered beyond the eight-session intervention of the QAT program. This pilot study
was designed to provide an additional intervention to the regimen of services the
participant was already receiving. Usual and customary treatment was provided to all
participants during the pilot study.
Pilot Study Costs and Compensation
Participants did not incur any costs related to participation in the pilot study. All
participants had established access to Archways for collateral mental health services.
There was no compensation for pilot study participants; however, light refreshments were
available at therapy sessions and at interactions involving completion of pilot study
assessments. At the completion of follow-up measurements, all participants in the pilot
study were invited to attend an informal meeting where light refreshments were served
and discussion was encouraged.
Informed Consent
All potential participants who responded to the invitation to participate in the pilot
study were given a copy of the informed consent form and asked if they required
assistance with reading the form. Two participants requested assistance with reading the
form and subsequently the informed consent was read aloud to them. The principal
investigator engaged participants in conversation and encouraged them to ask questions
to ascertain participants’ understanding of study risks, benefits, time expenditures,
expectations of participation and compensation. Participants were informed that the goal
of the pilot study was to determine if an intervention of counseling was helpful to

61

individuals with schizophrenia. Participants were questioned using open-ended questions
such as, “What do you think the counseling is for?” and “What do you think this pilot
study involves?” The principle investigator was assured of the participants understanding
and verbal consent through answers provided by the participants. After understanding
was confirmed verbally, written informed consent was obtained through the participant’s
signature on the consent form, signature of witness and photocopy provided to the
participant. Eight participants refused to keep a copy of the informed consent. These
participants were advised they could obtain one at any time through the principal
investigator or by requesting a copy from their case manager at Archways. Original
consents for all pilot study participants will be kept in a locked fireproof box at the
principal investigator’s home for a minimum of three years following completion of the
pilot study. Copies of the signed infonned consent forms were also placed in the
participant’s chart maintained by Archways’ Medical Records Department.
All pilot study participants are adults over the age of 18 and signed their own
adult consent forms. One consent document, written in English, was developed for this
pilot study; all QAT therapists, the research assistants, the principal investigator and pilot
study participants are English speakers. No waiver of written consent was sought. The
consent was prepared at a fifth-grade reading level, using Microsoft software FleschKincaid assessment, which is consistent with both 1RB requirements and the studies
regarding literacy and universal ease of understanding (Fisher, 1999), as well as
awareness of participants reading differences.
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Confidentiality ofData
As data was collected, the principal investigator, both research assistants and each
therapist maintained confidentiality of participants’ participation by safeguarding data
from casual observers and refraining from discussion about the pilot study except when
in regular study progress meeting. All therapists also signed an informed consent form
(see Appendix S for copy of the Therapist Informed Consent Form).
Removing participants’ names from the data collection forms and identifying each
form with participants, pilot study identification number only maintained confidentiality
of written data. Data collection forms maintained on site were kept in a locked portable
file box.
The principal investigator maintained at her residence pilot study-generated data
including, audiotape and paper documents on file in a locked, fireproof box throughout
the course of the pilot study and will maintain confidentiality and security of the data for
three years following completion of the pilot study analysis. For the duration of the pilot
study, documents generated on site from the pilot study remained in a locked cabinet in
the medical records department at Archways, or in a locked fireproof box at the residence
of the researcher. Transportation of data from the pilot study site to the principal
investigator’s home was made via locked file box in principal investigator’s possession.
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Chapter IV
Results
Introduction
The purpose of this pilot study was to examine the effects of the QAT
intervention on service users’ symptomatology and medication concordance scores.
Quantitative data obtained from PANSS scores were used as a measure of severity of
symptomatology and the PETiT, a self-report scale, was used as a measure of medication
concordance. Results of this pilot study are discussed in this chapter, including
demographic characteristics, descriptive statistics, and the results of the quantitative data
analysis. Quantitative and qualitative data obtained from the QAT program satisfaction
questionnaire (QPSQ) completed by experimental participants at the end of the
intervention is also presented. The experimental, Quatro adherence therapy group (QAT),
and the comparison, treatment as usual group (TAU), baseline and follow-up mean scores
were compared using Z-tests to analyze the differences in scores for symptomatology
severity and medication concordance. A repeated measures ANOVA was also done to
document the interaction effects of time X time and time X condition for both the QAT
and TAU groups. The baseline assessments were completed and scored before the
introduction of QAT and the follow-up assessments, at the completion of the
intervention.
A randomized, experimental pilot study design was used to examine if there was a
difference in the severity of symptomatology of schizophrenia or medication concordance
for individual participants who participated in an intervention of QAT. Archways, a local
community mental health center, was the only site where the research was conducted.
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Participants were recipients of services from Archways with a diagnosis of schizophrenia
or schizoaffective disorder.
QAT is a “structured pragmatic intervention based broadly on the techniques of
motivational interviewing and cognitive behavioral therapy” (Gray, Goumay et ah, 2001,
p. 13). The therapist and participant form a therapeutic relationship denoting the
interpersonal process, which develops in the nurse-patient relationship (NPR) described
by Peplau (1952). As part of the QAT process, aspects of the participants’ mental health,
illness and medication concordance are addressed. The process of this intervention
involves the therapist working to develop discrepancy and importance with the
participant as a means of resolving ambivalence towards medication taking behaviors and
treatment of mental illness. The major professor provided regular onsite supervision to
the adherence therapists.
Sample Data Results
Twenty-five participants were enrolled in the pilot study after signing the
informed consent. Randomization of participants was based on 26 participants due to the
error of two participants erroneously reporting enrollment to the onsite research assistant.
Subsequently two participants were dropped from the QAT group, one due to failure to
sign informed consent and the other due to incorrect diagnosis. These two participants,
randomized to the QAT group, received the intervention based on their requests to
participate in therapy. However, they were excluded from the data collection process. As
a result, for purposes of this pilot study, the QAT group consisted of ten participants and
the TAU group consisted of fourteen participants. One comparison participant was
dropped from the pilot study due to hospitalization for exacerbation of symptoms of
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schizophrenia. Subsequently 10 experimental participants and 13 comparison participants
were available for follow-up assessments. No participants left the pilot study voluntarily,
which is unusual for studies of mental health interventions. However, the small n and
stable nature of the participants’ relationship with Archways was likely influential in
maintaining the cohort.
Demographic Data
The frequency and percentage distribution of the participants by demographic
factors were computed at baseline to describe the sample characteristics (Polit, &
Hungler, 1999) and are found in Table 1. Demographic data were obtained through a
chart review of participants’ medical records. The pilot study sample was predominantly
male (78.3 %) and white non-Hispanic (65.2%). The mean age of the sample (n = 23)
was 42.9 years old and most (69.6%) lived in the community. Hospitalizations for
psychiatric care were somewhat varied, 52% of the sample had between 1 and 10
hospitalizations and 26% had between 11 and 30 hospitalizations. Considering education,
60% of the pilot study sample completed high school and 40% had less than a high
school degree or its equivalency.
Crosstabulation and Chi Square tests were conducted to compare baseline
categorical variables of diagnosis, sex, residence, race and years of education for
significant differences in the proportions of these variables across both groups (Polit, &
Hungler, 1999). The nonparametric test, Mann-Whitney U test (Polit, & Hungler), was
used for comparison of differences between the two groups on the variables of number of
hospitalizations and years of education. There were no significant differences between
the comparison, (TAU) and experimental (QAT) groups with respect to descriptive
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variables of diagnosis, sex, age, type of residence, number of hospitalizations, and years
of education,/? > .05. Results of the /-test analysis of age revealed no significant
difference between the QAT and TAU groups. Mean age for the QAT group was 39.4
with SD of 13.01. Mean age for the TAU group was 46.1 with SD of 10.08.
Table 1

Distribution ofDemographic Variables by Group
QAT

Variable

TAU

n

%

Male

8

80.0

10

6.9

Female

2

20.0

3

3.1

White non-Hispanic

7

70.0

8

1.5

Black non-Hispanic

2

20.0

4

0.8

Hispanic

1

10.0

1

.7

Community residence

6

60.0

10

6.9

Residential facility

4

40.0

3

3.1

n

%

Sex

Ethnicity

Housing

Table 1 continues.
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Table 1 (continued)
QAT

Variable

TAU

n

%

0

1

10.0

3

23.1

Ito 10

5

50.0

7

53.8

11 to 20

2

20.0

0

0.0

21 to 30

2

20.0

2

15.4

31 or more

0

0.0

1

7.7

Grammar / Middle School

0

0.0

1

7.7

Some years High School

3

30.0

5

38.5

High school / Equivalency diploma

5

50.0

6

46.2

Some college

1

10.0

1

7.7

Completed college

1

10.0

0

0.0

Schizophrenia

5

50.0

7

53.8

Schizoaffective Disorder

5

50.0

6

46.2

n

%

Hospitalizations

Years of Education

Diagnosis

Interestingly, one experimental participant terminated services with Archways,
during the pilot study: however, this participant completed QAT and returned to complete
follow-up assessments. Participant commitment to the pilot study and scheduling may
have been facilitated because of the small number of participants in the pilot study,
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frequent casual contact with pilot study participants and the onsite coordinating of
logistics by the onsite research assistant, who is an employee of the pilot study agency.
Research Question 1: Results
Research question 1; Is there a difference in the severity ofsymptomatology for
service users -with schizophrenia or schizoaffective disorder after participation in
the QATintervention?
The Positive and Negative Syndrome Scale (PANSS) measured the positive and negative
symptom syndromes and general psychopathology experienced by individuals with
schizophrenia and schizoaffective disorder to address the dependent variable of severity
of symptomatology (Kay, Opler, & Lindenmayer, 1989). The scale was administered
using the structured clinical interview component. A decrease in PANSS scores by 20%
would indicate a clinically significant improvement in symptomatolgy. Consistent with
other published studies, for comparison of the QAT and TAU groups, this pilot study
used three PANSS subscales: positive, negative, and general psychopathology.
Total subscale raw scores are converted to T-scores and percentile scores, which
are ascribed a comparative categorical description ranging from very much below
average to very much above average in relation to the normative group of 240 medicated
schizophrenics. Percentile scores for each subscale are based on the normal distribution
curves (Kay et ah, with Ramirez et ah, 2000) found in the normative group.
Baseline data, Positive and Negative Syndrome Scale. Baseline mean symptom
subscale scores were computed for the PANSS subscales to allow for baseline statistical
comparison and results are reflected in Table 2. For the PANSS, the experimental (QAT)
and the comparison (TAU) groups’ mean positive and negative symptoms did not differ
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significantly at baseline. There was significant difference between the groups on the
mean negative symptoms, p < .01 (Table 2). Mean score for the QAT group negative
subscale was 17.00 whereas the mean for the TAU group negative subscale was 22.38, at
baseline. PANSS manual interpretive guidelines allow comparison of this cohort at
baseline with the PANSS normative sample regarding severity of symptom syndrome
(Kay et al., with Ramirez et al., 2000). The sample scores were compared to the T-scores
and the percentile scoring of the normative group with participants’ scores ranging from
21st to 50th percentile. Compared to the normative group scores, the QAT group’s positive
and general subscale scores are in the average range and their negative subscale score
falls in the slightly below average range. The scores reflected in Table 2 indicate, the
TAU group had a higher severity of positive, negative and general symptoms when
compared to the QAT group measured at baseline. However, when compared to the
normative group scores, the TAU group’s positive, negative and general subscale scores
are in the average range.
Table 2
PANSS Subscales Baseline by Group
Group
PANSS Subscale

n

Mean

SD

QAT

Positive

10

17.90

5.34

TAU

Positive

13

18.54

5.50

QAT

Negative

10

17.00

4.16

TAU

Negative

13

22.38

5.20

t

0.28

**2.68

Table 2 continues. ** p< .01
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Table 2 (continued)
Group
PANSS Subscale

n

Mean

SD

QAT

General

10

39.70

8.26

TAU

General

13

40.30

8.42

Follow-up data, Positive and Negative Syndrome Scale. Descriptive statistics
were computed for the PANSS follow-up scores to allow for comparison. Change scores
for both the QAT and TAU groups were computed between the baseline and follow up
data for the PANSS subscales (Positive, Negative and General Psychopathology).
Table 3 shows statistics computed for the QAT group PANSS subscales from
baseline to follow-up. No significant differences were found for any of the three
subscales from baseline to follow up,/? > .05. Mean scores for the QAT group, decreased
for each subscale indicating some decrease in severity of symptomatology. However,
there is a relatively high variability of scores as indicated by the large standard deviation
(SD). This large SD may be reflective of a heterogeneous group. In comparison to the
PANSS normative group, the QAT group’s positive, negative, and general subscale
scores at follow up, each fall into the slightly below average group. This represents a
decrease in descriptive terms for both the positive and general subscales from baseline
scores in the average range. It is critical to note that the positive symptoms for the QAT
group decreased 22% from baseline to follow-up, which indicates a clinically significant
Improvement in symptomatology.
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Table 3
PANSS Subscales for QAT Group at Follow-up (n=10)
PANSS Subscale
Baseline

Follow-up

Mean

SD

Mean

SD

t

Positive Subscale

17.9

5.34

14.9

8.01

1.56

Negative Subscale

17.0

4.16

16.0

6.39

0.65

General Psychopathology

39.7

8.26

33.5

17.79

1.16

Table 4 shows statistics computed for the TAU group PANSS subscales from
baseline to follow-up. No significant differences were found for any of the three
subscales from baseline to follow up,/? > .05. Mean scores for the TAU group, decreased
for the positive and general psychopathology subscale indicating some decrease in
severity of symptomatology. Mean scores remained the same for the negative subscale.
There is a relatively high variability of scores as indicated by the large standard deviation
(SD). In comparison to the PANSS normative group interpretive guidelines, the TAU
group’s positive subscale score fell in the slightly below average range, but not at a
clinically significant level and the negative and general subscale scores remained in the
average range at follow-up.
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Table 4
PANSS Subscales for TAU Group at Follow-up (n=13)
PANSS Subscale
Baseline
SD

Mean

SD

t

18.5

5.50

14.8

5.17

1.98

22.38

5.20

22.38

7.63

0.00

40.3

8.42

35.4

9.88

1.75

Mean
Positive Subscale

Negative Subscale

General Psychopathology

Follow up

The two groups were compared to one another from baseline to follow-up to
determine significance of the intervention for the PANSS subscales. Table 5 shows mean
decreases for the PANSS subscales by group. For both the QAT and TAU groups there
were no significant differences (see Table5) in mean change scores from baseline to
follow-up. For all three PANSS subscales, p > .05, the intervention was not associated
with a statistically significant decrease in severity of symptomatology.
Table 5
PANSS Subscales Mean Change from Baseline to Follow-up by Group
n
Group
Mean
PANSS Subscale

SD

QAT

Positive Subscale

10

3.0

6.07

TAU

Positive Subscale

13

3.8

6.87

Table 5 continues.

73

Table 5 (continued)
Group
PANSS Sub scale

n

Mean

SD

QAT

Negative Subscale

10

1.0

6.67

TAU

Negative Subscale

13

0.0

9.64

QAT

General Psychopathology

10

6.2

16.96

TAU

General Psychopathology

13

4.9

10.13

t

0.28

0.23

Finally, in order to document the effects of time and time X condition
interactions, a repeated measures Anova analysis was run for baseline to follow-up data.
For both the QAT and TAU groups for the PANSS positive subscales there was a
significant difference over time (F = 6.055; p = .023) and no significance for time X
group interaction. For both the QAT and the TAU groups for the PANSS negative and
general psychopathology subscales there was no significance for time X group or over
time interaction, p > .05. Lack of significant findings for time X condition interaction
suggests that the groups did not change differently from one another over time on the
measurement of severity of symptomatology.
Research Question 2: Results
Research question 2: Is there a difference in medication concordance for service
users with schizophrenia or schizoaffective disorder after participation in the
QAT intervention?
The PETiT scale measured the participants’ self-evaluation of treatment to address the
dependent variable of medication concordance. The scale considers a number of
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subjective aspects of psychosocial functioning, quality of life, medication taking
behaviors and effectiveness of treatment (Voruganti & Awad, 2002). Total scores range
from 0 - 60. Higher scores indicate higher medication concordance.
Baseline data, Personal Evaluation of Transitions in Treatment. Baseline means
scores were computed for the PETiT to allow for baseline statistical comparison. The
PETiT baseline scores for the experimental, QAT, group revealed a mean of 40.10 with a
SD of 9.24 and for the comparison, TAU, group a mean of 40.07 with SD of 10.29.
There were no significant differences in the total scores for both groups on the PETiT
measure at baseline, t (21) = .01,/? < .99.
Follow up data. Descriptive statistics were computed for both groups on the
PETiT follow-up scores to allow for comparison. Additionally, mean change scores for
both the QAT and TAU groups were computed from baseline to follow-up and analysis
was conducted in order to compare the two groups.
Table 6 shows descriptive statistics computed for the QAT group on PETiT at
follow-up. No significant differences were found from baseline to follow up,/? > .05.
Mean PETiT total change scores for the QAT group show some decrease indicating a
decrease in medication concordance.
Table 6
PETiTfor QAT Group at Follow-Up (n-10)
Mean
PETiT Total

SD

Baseline

40.1

9.24

Follow-up

37.3

8.87

t

1.26
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Descriptive statistics computed for the TAU group at follow up are reflected in
Table 7. No significant differences were found from baseline to follow up,/? > .05. Mean
PETiT total change scores for the TAU group show some increase, indicating an increase
in medication concordance.
Table 7
PETiTfor TAU Group at Follow-up (n=13)
Mean
PETiT Total

SD

Baseline

40.1

10.29

Follow-up

41.6

8.63

t

.58

Paired and Independent Samples t-tests were computed for the PETiT mean
change scores from baseline to follow-up for both QAT and TAU groups to determine
significance in change of mean scores for medication concordance. Table 8 shows the
group means statistical comparison for the PETiT at follow up. Results of the comparison
of means change scores for PETiT, for both the QAT and TAU groups, reveal no
significance,/? > .05.
Table 8
PETiT Mean Change from Baseline to Follow-Up by Group
Mean
Group
n
SD
QAT

10

-2.8

7.02

TAU

13

+1.5

9.59

t

1.20

Finally, in order to document the effects of time, and time X condition interaction,
a repeated measures Anova analysis was calculated for baseline to follow-up data. For
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both the QAT and TAU groups for the PETiT scales there was no significant difference
over time, or for time X group interaction, p < .05. Lack of significant findings for time condition interaction suggests that the groups did not change differently from one another
over time on the measurement of medication concordance.
QAT Program Satisfaction Questionnaire (QPSQ) Data
Follow-up data collected after the conclusion of the intervention to evaluate service
user’s satisfaction with the program involved QAT group participants completing the
QPSQ. The satisfaction levels of two additional participants who participated in the QAT
intervention but were not included in the pilot study for analysis of intervention effect
were included in the analysis. These participants were included to capture all valid
experiences and to prevent rejection of possible negative experience. The QPSQ was
developed by the principal investigator and the major professor, in order to assess the
experimental participant’s level of satisfaction for both the QAT intervention and the
study experience. The instrument consists of 11-items self-rated by QAT group
participants on a Likert-type scale where a score of 1 = Strongly Disagree, 2 = Disagree,
3 = Not Sure, 4 = Agree, and 5 = Strongly Agree.
Frequencies and percentages were computed for the QPSQ scores in order to
quantify the data. A descriptive analysis was also conducted with a comparison of range,
mean and standard deviation for the QPSQ scores. Eight of the 10 positively worded
statements were scored as either agree or strongly agree by 100% of the QAT
participants. These scores indicate that all QAT participants report a high level of
satisfaction with the intervention, a subjective feeling of having a better understanding of
how to treat their mental illness, a positive experience of participating in the pilot study,
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and would recommend the counseling to a friend. Although 66% of the QAT participants
agree or strongly agree that they understand more about how their medication affects
them, 33% of the participants are not sure if they understand more about how their
medication affects them. Regarding the statement: I learned about managing my mental
health, 83% either agreed or strongly agreed and 17% were not sure if they had learned.
Table 9 reflects the results of the descriptive analysis conducted for QPSQ scores.
Table 9
Means, Standard deviation and Ranges for QAT Program Satisfaction Questionnaire
Scores (n=12)
Min.

Max.

Mean

SD

I learned about managing my mental illness

3

5

4.25

.754

I had a chance to ask questions

4

5

4.33

.492

I learned about my treatment

4

5

4.42

.515

I didn’t leam anything new about my treatment

1

2

1.33

.492

I understand more about how medication affects me

3

5

4.08

.900

My counselor was helpful

4

5

4.58

.515

I enjoyed being a part of the study

4

5

4.67

.492

People in the study treated me with respect

4

5

4.67

.492

I am satisfied with this counseling study

4

5

4.42

.515

I would recommend this type of counseling to a

4

5

4.50

.522

4

5

4.58

.515

Statement

friend
I have a better understanding of how to take care of
my mental illness
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On the QPSQ form, following the 11-item scale, two open-ended prompts were
posed with blank lines for write-in answers. The statements were: 1) The best things
about this counseling study are; and 2) A list of the things I wish had been different in this
counseling study. Every participant commented on at least one of the two prompts.
Responses were grouped for similarities for analysis. The participants’ responses to the
prompt statement concerning the best things about the counseling centered on their being
able to express feelings, ask questions, get answers and address problems. Three
participants responded to the prompt statement about what they wish had been different.
They responded by writing that the QAT program should include: more information
about medication, more time with the therapist and having the nurse practitioner or
psychiatrist work, hand-in-hand, in a manner similar to the counseling.
QAT Therapists ’ Fidelity to Protocol
Debbie Robson, QAT therapist and trainer at King’s College London and Dr.
Richard Gray, research fellow, King’s College London, evaluated seven random
counseling session audiotapes for fidelity to QAT protocol. The tapes were evaluated
according to the Therapist Fidelity Monitoring Protocol (Gray, & Robson, 2002). This
tool provides a score of the session ranging from 0 - 24, based on the therapists’
implementation of QAT interventions and the therapeutic techniques of cognitive
behavioral therapy and motivational interviewing. Scores from the seven audio-tapes
were: 23, 20, 19, 19, 18, 16, 13, and 12. Dr. Richard Gray’s assessment is that QUATRO
adherence therapy was delivered with a high degree of fidelity.
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Summary
A randomized, experimental pilot study design was developed to test if there was
a difference in the severity of symptomatology of schizophrenia or medication
concordance for individual participants who participated in an intervention of QAT. The
sample included 23 participants for this pilot study. The results of all statistical analyses
presented in this chapter indicated there was no significant difference between the QAT
and TAU groups on measures of severity of symptomatology and medication
concordance from baseline to follow-up after the completion of the intervention. The lack
of statistical significance between groups in follow-up data for the samples indicates the
intervention of QAT may not have influenced service users’ symptomatology and
medication concordance. However, it is important to note, that for the QAT group there
was a clinically significant reduction in the severity of positive symptoms of
schizophrenia.
In contrast to the quantitative analysis, the subjective program evaluation data
collected from all experimental participants, together with the two additional participants
who participated in the QAT intervention, was encouraging with regard to QAT and the
study experience. The qualitative data tend to support the concept that QAT involves the
development of a therapeutic interpersonal process between the client and the QAT
therapist.
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Chapter V
Discussion
Introduction
Results of the pilot study and its purpose are discussed in this chapter with
consideration of factors that may have influenced the outcomes. Findings of this pilot
study are compared with the literature review. Limitations of the pilot study, implications
for further study, and recommendations are also discussed. This pilot study found that the
measurements of severity of symptomatology and medication concordance did not vary
significantly from baseline to follow-up after the introduction of the QAT intervention
with the experimental group of service users with schizophrenia or schizoaffective
disorder. However, this pilot study established the feasibility of a larger scale study. The
qualitative data suggest the interpersonal relationship was viewed as a positive
experience related to service users’ understanding of their current illness situation.
Results of the qualitative data are also discussed. Finally, the significance of this study
and implications for the nursing profession are reviewed.
Pilot Study Purpose: Research Questions
The purpose of this pilot study was to examine the effect of the addition of an
intervention of QAT to service users’ usual treatment at a local community mental health
center on the dependent variables of severity of symptomatology and medication
concordance. The pilot study provided a previously tested intervention. The first research
question posed in this pilot study was to examine the effects of an intervention of QAT
on the service users’ symptomatology using PANSS to measure the severity of
symptomatology. Statistical analysis revealed there was no significant difference in
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participants’ symptomatology mean subscale scores or mean subscale change scores
when comparing baseline to follow-up. There was a clinically significant reduction in the
severity of positive symptoms for the experimental group.
This pilot study failed to replicate a number of studies completed over the past
several years, which revealed significant difference in symptomatology scores using the
PANSS resulting in a decrease in severity of symptomatology. Reasons why this study
failed to produce significant results may be due to the small sample size. According to
Rosenthal, Rosnow, and Rubin (2000, p. 5), a “small sample size may lead to failure to
detect a true effect, in which case .. .this line of investigation should continue with a
larger sample size. Additionally, outliers in a sample can influence the means in a manner
rendering it “not reflective of the sample,” thus skewing the data (Polit, & Hungler, 1999,
p. 463). However, the clinically significant reduction in severity of positive
symptomatology for this small sample indicates that the QAT program may produce
significant results with a larger sample.
The second research question posed examining the effect of an intervention of
QAT on service users’ medication concordance scores using the PETiT, a self-report
scale. Statistical analysis revealed there was no significant difference in participants’
medication concordance mean scores or mean change scores when comparing baseline to
follow-up. There are several reasons why the PETiT scale may have failed to show a
significant difference in medication concordance. The scale measures more constructs
than medication concordance. It may be that the 24-items on this scale related to
psychosocial functioning distracted from the 6-item medication concordance scale.
However, this should be with some caution since an increase in medication concordance
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for many individuals is linked with an increase in satisfaction with psychosocial
functioning and this scale targets the areas of psychosocial functioning targeted for
improvement by treatment (Voruganti, & Award, 2002). The link between medication
concordance and satisfaction with psychosocial functioning may also be mitigated by the
presence of side effects. Instructions for the use of this scale suggest that the last six
statements can be used as a subscale for medication compliance. However, no use of the
separate subscales has been substantiated.
Follow-up data were collected between one week and one day of the participants’
completion of therapy. It may be that sufficient time had not elapsed for the participants
to incorporate possible new behaviors of medication taking decisions in order to report
them. Although not substantiated as a subscale, the medication concordance section of
the PETiT, has a range of scores from 0 - 6. An evaluation of the medication compliance
section of the PETiT reveals a QAT group mean change score of .30 and SD of 1 Aland
for the TAU group, a mean change score of -.80 and SD of 2.44. The mean change scores
of less than one point on a six-point scale and the comparatively large SD indicate that
the means may not be reflective of the group.
Comparing the results of this pilot study to other published study results illustrates
a number of similarities, which are strengths of the study. This pilot study identified a
sample of individuals with schizophrenia and schizoaffective disorder, which was
statistically similar at baseline. This pilot study also utilized the SCI-PANSS, a wellknown tool to measure the severity of symptomatology in schizophrenia and
schizoaffective disorder, to optimize data collection and provide a basis for comparison
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with other similar studies utilizing the same instrument to detect change in
symptomatology.
Formal, manualized training and standardized QAT intervention forms were used
to provide therapy for the study participants similarly to other published studies. In this
pilot study, however, Dr. Richard Gray has made a determination that QAT was provided
in accordance with the fidelity monitoring protocol used in the U.K. It is significant to
note that the abbreviated training lasting 24-hours over three-days, prepared the therapists
to implement QAT. The combined educational preparation and training of the therapists
and onsite supervision permitted QAT to be delivered for the first time by non-nurse
providers in the U.S.A. Lastly, this study showed results of clinically significant results
of a 22% reduction in the severity of symptomatology, which compares favorably with
larger studies of this intervention. These encouraging comparisons are in contrast to a
large number of differences between this pilot study and the larger randomized controlled
trials (RCT) of QAT previously completed.
The differences between this pilot study and other RTCs of QAT are numerous. It
may be that the lack of statistical significance for this pilot study in contrast to larger
RCTs with significant positive outcomes is related to the small number of study
participants involved. A considerably larger number of participants, 120, were needed to
achieve a power level of .80, with the ability to compute statistical significance. The
small n of this pilot made statistical significance unlikely. In addition, this pilot study
stands in contrast to other studies of QAT, with its use of mental health counselors and a
licensed clinical social worker in lieu of community mental health nurses to provide the
intervention. In the U.S., there is not a large population of community mental health
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nurses who are generally available to provide this intervention. Anecdotal evidence
arising during the QAT therapist supervision sessions and noted on the service users’
evaluation on the satisfaction survey, suggests that the psychopharmacology preparation
of the QAT therapists may have been insufficient to meet some of the demands of the
intervention.
In preparation for study participation, QAT pilot study therapists received a 4hour psychopharmacology presentation given by the principal investigator. This
presentation was based on Dr. Richard Gray’s psychopharmacology overview utilized in
the medication management training in the UK. However, the formal educational
preparation of CMHN’s and QAT therapists differ greatly with regard to the
pharmacology component. Nursing education requires physiology and pharmacology in
contrast to the educational preparation of licensed clinical social workers and licensed
mental health counselors in the U.S.A. QAT therapists regularly attend informal
pharmaceutical presentations regarding psychotropic medications, but do not receive a
similar in-depth psychopharmacology component as compared to the nursing education
process.
One other contrast between this study and Gray, Wykes et al.’s (2003) study of
QAT is the number of contacts and exposure over time to health care professionals
trained in QAT and medication management services. In Gray, Wykes et al.’s study
mental health service users completed QAT and received the equivalent of what in the
U.S. would be ongoing case management services, from CMHN’s trained in medication
management for a longer period of time than was available for this pilot study. Time
between baseline and follow-up measurements in Gray, Wykes et al.’s study was 26
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weeks, allowing for considerably more contact over time. Time from baseline to follow
up in this pilot study was 8 weeks.
Theoretical Framework
Evidence from the satisfaction survey suggests that, as proposed, QAT therapists
were able to provide a therapeutic relationship similar to the nurse-patient relationship
described by Peplau. The theoretical model of Hildegard Peplau, guiding this pilot study,
proposed that the NPR involves a significant, therapeutic, interpersonal process that
“helps a patient to identify problematic elements in his current situation and to discover
and understand something about what is happening to him during his illness” (1952, p.
xiv). In this pilot study, the collaborative relationship between the QAT therapist and
participant represented the NPR. The qualitative data suggest support for the concept that
the relationships established in the QAT therapist-participant dyad was descriptive of the
NPR.
Many responses on the QPSQ, although limited in analytical application, can be
compared favorably with facets of Peplau’s theory of the NPR. The following statements
in italics regarding best things about QAT, obtained from prompts on the QPSQ, provide
evidence of clients identifying what Peplau refers to as, problematic elements, such as:
allowed me to express my feelings and concern mdlwas able to talk about my problem.
The development of a therapeutic interpersonal process during QAT is also supported by
participant statements on the QPSQ best things about QAT prompt, such as, worked
hand-in-hand, warm empathetic caring, trust, andfelt safe expressing my feelings without
fear. These prompted participant self-reported responses support the likely presence of a
significant therapeutic interpersonal process developed through QAT, between
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participants and QAT therapists. Peplau (1997) depicts the nurse employing health
teaching and enhancing learning for the patient during the working phase of the NPR.
Two participant’s responses to the best things about QAT prompt include: ask questions
and get answers and learn about medications correspond with Peplau’s depiction of
enhanced health learning and are based in the participants’ QAT experience.
The interpersonal process or collaborative relationship was proposed as the
vehicle for resolution of ambivalence to problematic elements in the individual’s
situation and integration of the present experience with other life experiences. This
concept of Peplau’s was evidenced in one participant’s concept of the best things about
QAT prompt, although it drudge up unpleasant memories, it yvas worth it. This
participant’s response also coincides with Peplau’s view of self as a process “gradually
examining and changing the contents of the self-system by checking self views against
reality” (Peplau, 1989c, p. 209), and is consistent with examining and changing the
contents of the self-view. Peplau reflects that, “insights, changed perceptions of one’s
situation and new views of self generated within a client cannot be observed and may or
may not be told to the nurse” (Peplau, 1988, p. 11). It may be that what Peplau views as
the product of the nurse-patient relationship were measured by this evaluation of the
QAT experience.
Limitations
The pilot study design, results and processes suggest a number of limitations.
Several emerging factors during this pilot study had the potential to influence data
collection, and removed rater blinding as a controlled variable. Limitations of this pilot
study include the following:
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1)

The small sample size of this pilot study might have influenced the results of
no significant findings.

2)

The possibility of outliers in a sample this size may have skewed the data and
led to a statistical analysis not representing the sample variables well.

3)

During follow-up assessment interviews, approximately 6 of the 10
experimental participants revealed their status to the raters, effectively un
blinding the study.

4)

Discussion between raters subsequent to scoring revealed significant
differences in participant’s rapport and self-disclosure between raters existed
and may have skewed the data. It is believed this factor was dependent on the
length and nature of past professional relationships between raters and specific
clients.

5)

Time constraints resulted in the follow-up assessments being conducted 8weeks after the beginning of the intervention. In specific participant situations,
this period essentially narrowed to approximately 6-weeks due to participants
beginning therapy sessions behind schedule.

Additional Interpretation
Although there were numerous limitations to this pilot study, there were also
some affirmative outcomes. These outcomes are anecdotal in nature and were brought to
the attention of the principal investigator through informal discussion between
participants in the QAT and TAU groups and staff at Archways at the completion of the
study. Following the conclusion of data collection, the principal investigator participated
in informal conversations with Archway’s staff who expressed noticing positive
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improvements in participants involved in QAT and questioning the principal investigator
when the TAU group participants would be starting QAT. Discussion revealed that TAU
participants had repeatedly questioned Archways staff about the start date, because they
had heardfrom the QAT group participants that QAT was great. Archway’s staff
described the improvements of QAT participants as: initiating discussion a bit more
frequently than prior to the start of QAT. Initiating conversation for these participants
indicates a decrease in the severity of the negative symptom of social withdrawal.
Further, through the study, staff at Archways became aware that several study
participants were able to benefit from therapy and will be continuing in therapy. This data
is viewed with great caution considering the positive professional relationships developed
over several years between Archways’ staff and the principal investigator and the desire
of the staff to provide positive feedback.
Archways plans to implement the intervention on an on-going basis, following the
conclusion of this pilot study. This will increase the occasions for concordance. The
mental health center will continue follow-up of the participants informally, analyzing any
further benefits of the intervention, through the usual and customary provision of services
to, and evaluation of treatment response for the QAT group participants of this pilot
study. The informal continuation of the pilot study at this site will provide the agency and
service users increased opportunities for concordance, hopefully leading to decreased
severity of symptomatology, and providing a resource for relapse prevention and health
promotion through QAT’s focus of increasing concordance.
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Implications
This pilot study is significant to advanced nursing practice for several reasons,
despite the lack of significant results. Many people with schizophrenia live with
distressing symptoms that disrupt their thoughts, emotions, and ability to function
independently, and place them at a high risk for suicide (Simon, 2002). Many master’s
prepared psychiatric nurse practitioners are in the position of monitoring and altering
drug therapies and initiating appropriate therapies for individuals with schizophrenia
(Florida Department of Health, 2003). Research suggests that medication combined with
psychosocial interventions for people with schizophrenia make a significant impact on
health outcomes and assist some individuals to recover a relatively higher level of social
functioning (McCann, 2001).
Investigating medication concordance interventions is critical to improved
healthcare outcomes for individuals living with the illness of schizophrenia. This pilot
study contributes the beginnings of research in the U.S. for QAT, an evidence-based
program of care delivery for people with schizophrenia that promotes concordance. This
study contributed to the promotion and discussion of symptomatology of schizophrenia
interventions and medication concordance at Archways. The nursing professions’
promotion of mind, body and spirit-focused health care was enhanced by promoting the
concept of medication concordance and nurse-patient therapeutic intervention in health
care relationships as a standard of care. The nursing profession’s goals are promoted
because presenting the concept of medication concordance encourages discussion of the
client’s worldview, respect for individual’s receiving care, autonomy and the value of the
client’s perspective and experience in the therapeutic relationship.
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Although this pilot study did not replicate the outcomes of previous studies of
QAT, training in assimilating the techniques of motivational interviewing and the spirit
of concordance was provided to study therapists. This pilot study exposed Archways’
staff to the use of a collaborative approach in providing health care, which has been
shown to be consistent with improved health care outcomes (Gray, Wykes, et al., 2002,
Healey, et ah, 1998). This pilot study made available, to participating service users
information about their illness and treatment and discussed tailoring regimens to the
needs of the service user. This is consistent with the ethics of nursing practice and
informed consent to treatment. Importantly, a thoughtful assessment of service users’
beliefs, experiences concerns, fears, goals, and values was provided to the QAT
participants. This is consistent with the nursing professions’ promotion of ethical care
(ANA, 2001), which is responsive to the worldviews of the service users, to whom health
care services are provided.
Results in this pilot study suggest that a larger scale RCT is needed to produce
statistically significant results. This study also demonstrated that it is feasible to deliver
QAT in the U.S.A. at a community mental health center with mental health service
providers other than nurses. This therapy is a Medicaid-covered form of short-term
individual therapy, which can be provided to individuals for whom therapy has been
recommended. This pilot study contributed to the provision of effective management of
schizophrenia at this community mental health center, because it offered a user-centered
evaluation of pharmacological interventions, uncomplicated information, and the use of
both motivational interviewing and cognitive behavioral techniques to help service users
make educated decisions about their treatment. There is evidence that routinely
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incorporating these concepts into the fundamentals of mental health care improves
service users’ mental health (Gray, & Odunlade, 2002).
Further research is needed on a larger scale to determine which service users are
most likely to benefit from this intervention and whether or not the results of the UK
studies can be replicated in the US. Funding and training of individuals to provide QAT
is an issue that must be addressed as well. The training provided to QAT therapists for
this pilot study was an abbreviated, 3-day form of what in the UK is usually a 10-day
training program for CMHNs. The QAT therapists, who were master’s prepared
counselors with prior training in interpersonal therapeutic techniques, were seen by the
trainers to be at an advantage in acquiring QAT’s specific blend of MI and CBT active
listening skills in comparison with the CHMNs attending training in the U. K.
Conversely, the QAT therapists were at a disadvantage in the realm of medication
education and psychopharmacology when compared to the CMHNs in the U. K. These
issues can be addressed with targeted interventions for trainee groups. Based on the
positive qualitative data, the lack of a large enough sample to produce statistically
significant results and timing issues of data collection, further study on a larger scale
aimed at replicating the results of the QAT studies in the UK is implicated.
Implications for further study include a discussion of outcome measurements. The
PETiT was developed to measure service users’ subjective response to treatment. The
items reflect many concepts that are of importance to service users’ recovery and
psychosocial functioning, many of which are responsive to medication. The total scale
was used in this pilot study and there is a recommendation by the authors to consider
using the medication adherence subscale (Voruganti, & Award, 2002), although
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statistical evaluation was not available in the literature for this subscale. Further studies
may consider obtaining the DAI (Hogan, Awad & Eastwood, 1983), which was used in
previous studies as a scale predictive of drug compliance or the PETiT subscale for
medication compliance. Further study may also first consider the development of a tool to
measure a subjective level of concordance using the components of concordance
specified in the literature.
Summary
In this final chapter, the purpose and findings of the pilot study and its results
were discussed with consideration of several factors that may have influenced outcome.
Findings were discussed with regard to limitations of the pilot study, implications for
further study, and for the nursing profession. Recommendations were presented in
consideration of the pilot study outcomes and research. The qualitative data suggested the
interpersonal relationship developed through the intervention of QAT was a helpful
influence on service users’ understanding of their current illness situation. The health
care community has increasingly relied on the methods of scientific inquiry to produce
improvements in treatment available for service users with severe and enduring mental
illness. Future research regarding the promotion of concordance in provider - health care
recipient relationships has the potential to positively influence many variables that
contribute to health care outcomes and develop new evidence-based standards of care that
are responsive to the multicultural needs of health care service users.
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919 N.E. 13th Street • Fort Lauderdale, FL 33304

PROGRAMS ACCREDITED BY CARF

September 25, 2003

Stephanie Hall Ford, RN, BSN
Florida International University,
Graduate School of Nursing
609 Southwest 19th Street
Fort Lauderdale, Florida 33315

Dear Stephanie,

I am pleased to inform you that your request to conduct research regarding the
implementation and evaluation of Adherence Therapy for individuals with mental
illness here at Archways, Inc, has been approved. I understand that the staff
training and provision of the intervention under study, will take place on site and I
am happy to provide suitable amenities.

My staff and I look forward to working with you on this study.

Regards,

Andrea Katz, LCS/V,
Chief Executive Officer

Providing Quality Behavioral Healthcare Since 1983
ANNIE R.P. SEYMOUR, BS.N
Chairperson

ANDREA KATZ, LCSW, BCD
Executive Director / CEO
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Division of Sponsored Research & Training

FIU

Office of Research Compliance, MARC 430

Florida International University

Miami's public research university

MEMORANDUM
To:

Stephanie Hall Ford

CC:

Kathryn Hoehn Anderson

From:

Niurca E. Mirquez-Castro, Administrator Institutional Reviev

Date:

March 25,2004

Proposal Title:

Examining The Difference in Community Mental Health Serv
Symptomology, and Concordance with Medication Regimens After
Completion of QUATRO Adherence Therapy,
Approval#

031704-01

The Institutional Review Board of Florida International University has approved your study for
the use of human subjects. Your annual report will be due March 2005. As a requirement of
IRB approval you are required to:
1) Provide immediate written notification to the IRB of:
• Any additions to, or changes in the procedures involving human subjects,
# Every Serious opnimsual or unanticipated adverse event as well as problems with the rights
or welfare of the human subjects. Confirmation of receipt of serious AE reports must be
made with the IRB office.
2) Utilize copies of the date stamped consent documents) for the recruitment of subjects and
receive annual renewal of consent documents.
3) Receive annual review and re-approval.
Special Conditions:

three consent forms and one invitation letter approved for use.

Please note your approval number is indicated above. For further information, you may contact
the IRB Coordinator by email at irbiacuc@fiu.edu or visit the DSRT - Human Subject web site
at www.dsrt.fiu.edH.
.
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ARCHWAYS
PORT LAUDERDALE, FLORIDA

CONFIDENTIALITY STATEMENT

..SiZPUMIF,

_

hereby acknowledge that

the legal and ethical obligations imposed upon me as a volunteer at
Archways have been fully explained to me,

I understand that the

■effective maintenance of confidentiality of a member's clinical
program facilities.

I further understand that failure on my part

to preserve the patient's right to confidentiality may result in
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Flopjda JinwuTicjNuUNjyERsrry .
Miami'spublic research university

Dear

__________________ ,

You are being invited to be in a research study. The study is to find out if 8 weeks of a new kind of individual counseling
is helpful to people. If you decide to be in the study, the services you get from Archways will not be affected in any way.

The investigator of the study is Stephanie Ford. The same Stephanie Ford who used to work in Intake at Archways. I
(Stephanie) am a student now at Florida International University, in the Graduate School of Nursing. The study includes
adults who go to Archways for mental health care.
individuate who agree to be in the study will each have their own counseling sessions. The counselors are Marie
Fairchild or Jeanne Ansourian at Archways. You will start the counseling in either March or June 2004. This is a new
kind of counseling program developed in England. This counseling helps individuals gain a better understanding of
themselves and their mental health.
The counseling meetings are for one hour, one time each week. The program lasts for eight weeks. You will make
appointments with your counselor for times that are good for you. The counseling involves talking about things that you
like and don’t like. Things like medicine, emotional problems, hospitals, and your life. You will be asked about your
hopes and goals for the future. Talking about how you make plans and reach goals in your life is part of the counseling
too.
It Is hoped that this new type of counseling will help you. If you want to be in the study, you will have two interviews. The
Interviews are about mental health symptoms you may have. The interviews take about one hour. One interview is In
March or April and the second interview in June.
You will also fill out a form that has questions about what you think about medications you take. You can ask questions
about the form If you want help. The form has questions and a list of answers. You answer the questions by making a
circle around the answer you pick. You will be asked to fill out tills form in March and then again in June.
• '
Your name wifi not be on any of the documents about you. AB Information will be labeled with a code number, not your
name. After the study, we will look at all the Information we collect We hope to find out how the counseling either helped
or did not help. I (Stephanie) will give a talk at Archways about what we find out after the study is over. You are invited to
the talk to hear about it
:
'
There Is no cost to be In the study. We think you will like the counseling meetings. By being in the study, you will help us
see if this new kind of counseling Is a help to you.

There will be refreshments Ike coffee, water arid Juice and a few snacks at the meetings and' the counseling sessions. ■
NEW PAGE PLEASE,

Bltayne Bay Camp»

ScbodrfNsmtag ' '
College of Health sod Urban Afiain
151« Swet • North Miami, FL53181 • TA 005) 915-5915 • Fw 005) M9-5395-
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In this envelope, you will find a card that has boxes to mark. When you mark an X in one of the boxes, it will show me
what you want to do about being In the study. If you decide not to be in the study, it is okay and the services you get
from Archways will not be affected in any way.
Please mark an X as your answer in one of the boxes on the card in this envelope.
Next, please take this card with you the next time you go to Archways. Then put the card in the box by the receptionist at
Archways. She will show you where the box is, if you don’t see it!

if you mark the box: YES, INTERESTED, I will get in touch with you and talk to you about being in the study. I will either
call you on the phone or see you when you are at Archways. If you want to, you can still decide no after talking with me.

If you mark the box: NO, NOT INTERESTED, that's okay and I will not get in touch with you. Thanks for reading the
tetter and thinking about it

if you do not put the card in the box, then I will not get a card from you. If I don’t get a card from you, then I will get in
touch with you to see if you are interested.

You can also leave a message for me with the receptionist at Archwaysl If you have a question for me, tell the person at
the reception desk and they will call me with your message. I will be happy to answer any questions you have about the
study.

If you have further questions and want to talk to someone at Florida International University about this study, please
contact Dr. Kathy Anderson at 1-305-019-5376. If you still have questions and need to talk further, you can caH Dr.
Bernard Gerstman. He is the Chairperson of the Florida International University, Institutional Review Board. His phone
number is 1-305-348-3115 or 1-305-348-2494.
Thank you for considering being in the study.

Regards,

Stephanie Ford,

ANBOVSD
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APPBOVED
RESPONSE POSTCARD
ABOUT THE STUDY
OF A NEW KIND OF COUNSELING.
TO: STEPHANIE FORD

FROM:

Print your name on the above line
FILL OUT THE CARD BY MARKING A BOX BELOW.
□

□

YES, INTERESTED!
PLEASE GET IN TOUCH WITH ME!
I WANT TO HEAR MORE ABOUT THIS!

NO, NOT INTERESTED!
THANKS, BUT DON’T CALL ME!
MAYBE SOME OTHER TIME,
I KNOW'THISISOKAYTOO!

PLACE CARD IN BOX BEHIND RECEPTION DESK
AT ARCHWAYS

(response postcard enclosure)
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FOLLOW UP CONTACT SCRIPT
I am Stephanie Ford. I sent you an invitation and you sent me the card back saying you are interested. Do you
have any questions for me?
Would you like to talk about signing a form saying that you want to be in the study?
OR
I am Stephanie Ford. I sent you an invitation, but didn’t get a card from you.
The invitation tetter you got was about being in a research study. The study is to find out if a new kind of individual
counseling is helpful to clients of Archways.
I am a student now at Florida International University, in the Graduate School of Nursing. The study is being done
here at Archways.
Archways clients who want to be in the study will have their own counseling. The counselors are Marie Fairchild or
Jeanne Ansourian at Archways. This is a new kind of counseling program developed in England. This counseling
helps individuals understand themselves better.
If you decide to be in the study, the services that you receive now from Archways will not be affected in any way.
I hope that this new type of counseling will help you. If you want to be in the study, there will be two interviews.
The interviews last about one hour and are about mental health symptoms you may have. One interview is in
March and, the second interview will be in June.
You will also be asked to fill out a form about medicine you take. The form has questions and lists of answers.
You will be asked to fill out the form in March and then again in June.
Your name will not be on any of the information about you. All information will be labeled with a number, not your
name. After toe study, we are going to look at all toe information we collect We hope to see how the counseling
either helped or did not help. I will give a talk at Archways about what we find out after toe study is over that you
are invited to.
The counseling meetings are for about one hour, one time each week. The program lasts for eight weeks. You will
be able to make appointments with your counselor for times that are good for you. The counseling involves talking
about things that you like and don’t like. Things like medicine, emotional issues, hospitals, and your life. You will
be asked about your hopes and goals for toe future. Talking about how you make plans is part of toe counseling
too.
There is no monetary cost to be in the study. Being in the study, will help us see if this new kind of counseling is a
help to you. There will be refreshments like coffee, water and juice and a few snacks at the meetings and toe
counseling. Jean and Marie will have a refrigerator set up for this.
You will only be in toe study, and have this counseling if this is something you want to do. If sign up for the study
but later want to quit being in toe study, you can just let your counselor or case manager know. The treatment you
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receive now will not be affected in any way if you decide not to be in the study. No one would be upset if you
decided to quit it is your choice.
If you don't want to be in the study you can tell me now or if you want, you can think about it more and leave a
message for me at the receptionist desk sometime today please.
If you have further questions and want to talk to someone at Ronda International University about this study,
please contact Dr. Kathy Anderson at 1-305-919-5376. If you still have questions and need to talk further, you can
call Dr, Bernard Gerstman. He is the Chairperson of the Florida International University, Institutional Review
Board. His phone number is 1-305-348-3115 or 1-305-348-2494.
i can leave these numbers for you if you want to make calls. You can ask your case manager for help making the
calls.
Would you like to talk about signing a form that says you want to be in the study?
If no then -> Thanks for talking to me, please leave a message for me sometime later today. If I don’t get a
message, I will know that you are not interested right now. Is that okay.
If yes then -> Take a took at this form with me and lets read through it I want to make sure you understand the
form and what your part is in the study.
Questions will be answered and information will be clarified before asking subject to sign consent
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Florida International University

Miami’s public research university
SUBJECT CONSENT TO BE IN A RESEARCH STUDY
Title: To find out i a new kind of individual counse&ng helps people feel better about themselves.

You are being asked to be a subject in a research study. The purpose of the study is to see if a new kind of
counseling is helpful to adults who receive mental health care.
The principal investigator of the study is Stephanie Ford. She is a graduate student at Florida International
University (FIU) in the School of Nursing. The study will include adults who go to Archways for mentí
health care. Being a part of this study will not affect the health care or any services that you get from
Archways.
Individuals in the study will have 8 weeks of individual counseling. Half of the individuals in the study will
receive the counseling from March to June. The other half wdl receive the counseling ton June to August
The counselors are Marie Fairchild and Jeanne Ansourian, here at Archways.
If you decide to be in the study, you wsB also have two interviews. One interview is in March or April and the
other is in June. The interviews are about mental health symptoms you may have. The interviews take
about one hour and wW be scheduled with you.
The counseling sessions are for one hour, one time each week. The program taste for eight weeks. You will
make appointments with your counselor for times that are good for you. The counseling involves talking
about things that you like and don’t like. Things like medicine, emotional problems, hospitals, and your life.
You w» be asked about your hopes and goals for toe future. Talking about how you make plans is part of
the counseling too.
You'will ateo fiH out a form that has questions about what you think about the medications you take. You
can ask questions about the form tf you want help. The form has questions and a 1st of answers. You
answer the questions by making a circle around the answer you pick. You wifi be asked to fin out this form
in Mach and then again to June.
The form that you « out and the notes that we write will not be labeled with your name. You and your
counsel» wB keep any notes you make. We wB abo get information from your records at Archways.
Information about what type of place you Uve, your age, your sex, your race, years of school and how
many fees you ha« been in fte hospital. All of the infamafat about you wi be Iabeted with a code

We think participating in this study will be helpful to you. You can ask any questions you want any time you
want to. Ttee is no monetary cost, to be in to study. The services you get now ton Archways wi not be
affected in any way. We think you will like the counseling meetings. We also think the form you wil fiH out is
easy and won’t cause you stress.

School of Nursing
College of Health and Urban Affiun
Biscayne Bay Campus 3000 N.E. 151« Street • North Miami, FL 33181 • Tel: (305) 919-5915 • Fax: (305) 919-5395
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By being in the study, you wili help us find out if this counseling is a help to you. There will be coffee, water,
juice, and a few snacks at the meetings and counseling. At the end of the study, we will have a meeting for
everyone in the study.
At this last meeting the principal investigator, Stephanie Ford will talk about the results of the study. We will
also have refreshment then.
You can decide later, after you sign this form, that you want to quit being in the study. If you do, you can tell
your counselor or your case manager. If you quit the study, it will not affect the health care or any
services that you get from Archways. Also, you can still come to the last meeting to hear about the
study. It is okay and no one wiB be upset if you decide to quit
We might ask you if we can make a voice tape recording of one of your counseling sessions. A researcher
named Dr. Richard Gray will listen to the tape recording to find out how the counselor may have helped
you. The tape will not have your name on it
If you agree to tape record a session both you and your counselor will sign a form saying it is okay to tape
record toe session. You can refuse this. If you don’t want to have a session taped, it is okay. We only want
to tape record a counseling session, if you give permission.
If you have further questions and want to talk to someone at Florida International University about this
study, please contact Dr. Kathy Anderson at 1-305-919-5376. If you still have questions and need to talk
further, you can ca» Dr. Bernard Gerstman. He is toe Chairperson of the Florida International University,
Institutional Review Board. His phone number is 1-305-348-3115 or 1-305-348-2494.
By signing your name below on this form, you are saying that all of your questions have been answered in
a way you like. Also, that you understand what your responsibilities are in toe study. Your signature on this
form also means toat you have an understanding of your rights and that you would like to be in the study.

Signature of Participant

Printed Name

Date

I have explained the research procedure and subject rights. I have answered aR questions asked by the
participant I have offered toe participant named above a copy of this informed consent form.

Signatee of Wtirim

Printed Name

""Date

SHOVED
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DEMOGRAPHIC DATA COLLECTION FORM FOR QAJ STUDY
SUBJECT STUDY ID NUMBER

1. DIAGNOSIS:
Axis I:

2. SEX:
3. RACE:
4. AGE:
5. DATE OF BIRTH:
6. TYPE OF RESIDENCE:
7. NUMBER OF HOSPITAUZATIONS:
8. YEARS OF EDUCATION:
9. MEDICATION REGIMEN:
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Syndrome Scale and Copyright Agreement.
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Examples of Structured Clinical Interview - Positive and negative Syndrome Scale
Data on Anxiety (G2)
1. Have you been feeling worried or nervous in the past week?
IF YES, skip to question 3. IF NO, continue.
2.

Would you say you are calm and usually relaxed?
IF YES, skip to question 8. IF NO, continue.

3. What’s been making you feel nervous (worried, not calm, no relaxed)?
4. Just how nervous (worried, etc.) have you been feeling?
5. Have you been shaking at times or has your heart been racing?
6. Do you get in a state of panic?
7. Has you sleep, eating or participation in activities been affected?

Data on Depression (G6)
102. How has your mood been in the past week: mostly good, mostly bad?
IF “MOSTLY BAD,” skip to question 104. IF “MOSTLY GOOD,” continue.
103. Have there been times in the past week when you were feeling sad or unhappy?
104. Is there something in particular that is making you sad?
105. How often do you feel sad?
106. Just how sad have you been feeling?
107. Have you been crying lately?
108. Has you mood in any way affected your sleep?
109. Has it affected your appetite?
110. Do you participate less in activities on account of your mood?
111. Have you had any thoughts of harming yourself?
IF NO, skip to question 114. IF YES, continue.
112. Any thoughts about ending your life?
113. Have you attempted suicide?

Copyright ©1992,1999 Multi-Health Systems Inc. All rights reserved. In the USA, P.O. Box
950, North Tonawanda, NY 14120-0950,1-800-456-3003. In Canada, 3770 Victoria Park Ave.,
Toronto, ON M2H 3M6,1-800-268-6011. Internationally, +1-416-492-2627. Fax, +1-416-4923343. Reproduced with permission.
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Example of Rating Scale Criteria for Depression (G6) on PANSS
Depression
There are feelings of sadness, discouragement, helplessness, and pessimism.
Basis for rating - verbal report of depressed mood during interview and its observed influence on
patient’s attitude and behavior as reported from primary care workers or family.
Score
1
2

Rating
Absent
Minimal

3

Mild

4

Moderate

The patient has distinct feelings of sadness or hopelessness, which
may be spontaneously divulged, but his or her depressed mood has
no impact on his or her behavior or social functioning, and he or she
can usually be cheered up.

5

Moderate
Severe

The patient’s mood is distinctly depressed ands associated with
obvious sadness, pessimism, loss of social interest, psychomotor
retardation, and some interference in his or her appetite and sleep.
The patient cannot be easily cheered up.

6

Severe

The patient’s mood is markedly depressed mood is associated with
feelings of misery, hopelessness, worthlessness, and occasional
crying. There is also major interference with his or her appetite
and/or sleep as well as normal motor and social function, possible
signs of self-neglect.

7

Extreme

Depressive feelings seriously interfere with most major functions.
These manifestations include frequent crying, pronounced somatic
symptoms, impaired concentration, psychomotor retardation, social
disinterest, self-neglect, possible depressive or nihilistic delusions
and/or possible suicidal thoughts or actions.

Criteria
The question does not apply.
Questionable pathology, the patient may be at the upper extreme of
normal limits.
The patient expresses some sadness or discouragement when
questioned, but there is no evidence of depression in the patient’s
general attitude or demeanor.

Copyright ©1992,1999 Multi-Health Systems Inc. All rights reserved. In the USA, P.O. Box
950, North Tonawanda, NY 14120-0950,1-800-456-3003. In Canada, 3770 Victoria Park Ave.,
Toronto, ON M2H 3M6, 1-800-268-6011. Internationally, +1-416-492-2627. Fax, +1-416-4923343. Reproduced with permission.
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SENT ELECTRONICALLY
July 26, 2004

Florida International University
11200 S.W. 8* Street
Miami, FL 33199

Attention: Stephanie Ford

LICENSE AGREEMENT
Multi-Health Systems Inc., hereinafter referred to as “MHS”, hereby grants to Stephanie Ford
(“Licensee”), the right to use the SCI-PANSS and PANSS Manual for Publication purposes only as
hereinafter agreed.

A.

DEFINITIONS

1.

In this Agreement, “Confidential Information” means any information concerning the Test
described in Section 3 herein, and any information concerning the business of MHS, including
but not limited to, information on current products, future products, research and development,
licensees or distributors of MHS, and any information that is third party proprietary information
given to Licensee, whether such information is disclosed in written, oral or other media form to
Licensees or its employees, including independent contractors.

2.

“Publication” represents a Masters Thesis entitled A Pilot Study Examining the Difference in
Community Mental Health Service User's Symptomatology and Concordance with Medication
Regiments after Completion ofthe Quatro Adherence Therapy Intervention.

3.

“Publisher" represents a publishing company named Florida International University, having
offices at 11200 S.W. 8* Street, Miami, FL 33199.

4.

“SCI-PANSS” and “PANSS Manual” means the Structured Clinical Interview for the Positive
and Negative Syndrome Scale, and the Positive and Negative Slyndrome Scale Technical Manual,
hereinafter collectively referred to as the “Test”, published by MHS, in any form or medium,
including without limitation, test items, normative data, scoring algorithms, patterns and
directions, score conversion tables, rating criteria, printed profile and interpretive reports, training
manuals and numerical and graphic data relating to administration, scoring and interpretation of
the Test, and includes all versions, revisions, translations, standardizations or adaptations of the
Page 1 of 6
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foregoing. The Licensee acknowledges and agrees that all right, title and interest in and to the
Test shall remain vested in MHS and that MHS will be the first owner of the copyright in any
Format. These rights are protected by Canadian intellectual property laws, international treaty
provisions and other applicable national laws. During or after the term of this Agreement, the
Licensee shall not, in any . manner, infringe such rights or contest or dispute the validity,
enforceability or ownership thereof. The permission granted herein shall not constitute a sale of
whole or part of the Test.

B.

PERMISSION

MHS grants to Licensee, subject to the terms and conditions of this Agreement:
1.

Permission to reproduce Test items in the Licensee’s Publication as set out in Schedule “A” and
Schedule “B”.

C.

TERMS AND CONDITIONS

Permission granted in Section B above is given subject to the following terms and conditions:
1.

If applicable, for each permission granted in Section B, Licensee shall submit to MHS a proposed
draft layout of the Test items showing the format in which the Licensee intends to use the Test
items in the Publication approved pursuant to this Agreement MHS shall notify Licensee in
writing of its approval, or disapproval, within five (5) business days of receipt of submission. A
submission shall hereafter be referred to as a “Format” and a submission approved by MHS for
use shall be referred to as an “Approved Format”.

2.

Only an Approved Format may be reproduced in the Publication. The Approved Format that may
be reproduced for use in the Research Study is attached to the Agreement as Schedule B.

3.

The permission granted herein is only for the Publication approved pursuant to this Agreement.
Under no circumstance shall an Approved Format be used in any Publication other than that
approved pursuant to this Agreement.

4.

Any pages that contain reproductions of the Approved Format will bear the appropriate copyright
notice. This copyright notice is to appear as:
Copyright ©1992, 1999 Multi-Health Systems Inc. All rights reserved. In the USA, P.O. Box
950, North Tonawanda, NT 14120-0950,1-800-456-3003. In Canada, 3770 Victoria Park Ave.,
Toronto, ON M2H3M6,1-800-268-6011. Internationally, +1-416-492-2627. Fax, +1-416-4923343. Reproduced with permission.
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5.

Except as otherwise provided under this Agreement, the Licensee shall not disclose, use or allow
the use of any part of the Confidential Information to any person, institution, firm or corporation.
Licensee shall use the Confidential Information strictly for the purpose of publishing the
Publication approved pursuant to this Agreement.

6.

MHS extends the permission to reproduce the Test items pursuant to this Agreement to the
Publisher of the Publication and to distribute the Approved Format of the Test items by virtue of
sales and distribution of the Publication. Licensee shall forward a copy of the Publication to MHS
for its records.

7.

The Publisher and/or the Licensee are not permitted to translate, or permit and/or hire a third
party to translate, the Test items without a prior written approval of MHS.

8.

This Agreement shall be in effect immediately upon fall execution and shall remain in effect
while the Publication remains in print. The Licensee shall be required to obtain a separate
License Agreement for future revisions of the Publication if the Publication will contain the Test
items permitted pursuant to this Agreement

9.

MHS represents and warrants that it has all rights necessary to grant the permission granted to the
License® hereunder.

10.

Upon termination of this Agreement, the Licensee shall destroy or return to MHS all Confidential
Information in its possession or control, unless Licensee obtains written approval from MHS to
maintain the Confidential Information in its possession or control. Sections 4 and 5 shall survive
termination of this Agreement

11.

Without limiting the generality of the foregoing paragraph, the Licensee shall not use whole or
part of the Test in the development of another psychometric instrument.

12.

To the extent permitted by applicable federal and state or provincial law, the Licensee shall
indemnify, defend and hold harmless MHS, its directors, officers, employees, and agents from
any and all claims, suits, damages, liability, losses, fees and expenses (including reasonable
attorneys’ fees) resulting from or arising out of any act or omission of the Licensee under this
Agreement

13.

The Licensee shall pay MHS a license fee of US $0.00 far the reproduction of the Approved
Formats permitted to be reproduced hereunder and as specified in Schedule A. There shall be no
refund, credit or offset of any license fee paid.

14.

The fee payable under paragraph 13 above shall be payable by the Licensee within twenty (20)
days of fall execution of tins Agreement. Each submission license fee payment or notice required
hereunder should be sent by registered delivery to: Multi-Health Systems Inc., P.O. Box 950,
North Tonawanda, NY 14120-0950, to the attention of the Contracts and Rights Coordinator.
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St. Joseph's Healthcare

Ha
mil hi
Hamilton
It is an honour to serve our community.

January 30, 2004

SENT VIA EMAIL AND POST
Ms. Stephanie Ford
609 South West 19th Street
Fort Lauderdale, Florida
USA
33315-2049
Dear Ms. Ford:
RE:

PERSONAL EVALUATION OF TRANSmQNS.IN TREATMENTlPED.TI

Please be advised that I have forwarded the PETiT instrument, instructions and scoring
key to you via email. You are welcome to use the PETiT in your Thesis.
Best of luck in your future endeavours.
Sincerely,

Kathryn McColl (Ms.) for
L Voruganti, M.D.
LV:km

Ends.

Centre for Mountain Health Services
Member, St. Joseph's Health Care System
Affiliated with the Faculty of Health Sciences, McMaster University

100 West 5th, Box 585, Hamilton, Ontario, Canada L8N 3K7
Phone: 905.388.2511 Fax: 905,381.5601
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PERSONAL EVALUATION OF TRANSITIONS IN TREATMENT
(PETiT)
:

Instructions for Users

INTRODUCTION

PETiT Is a short, self-administered rating scale designed to capture subjective aspects
of quality of life of psychiatric patients over a relatively shorter time frame, i.e. one to
six months time. It is useful to arrive at a cross sectional profile of the subjective
aspects of quality of life, and also to capture the changes over time.
GENERAL DESCRIPTION

The scale has 30 items: the first 24 items tap into various subjective aspects of
psycho-social functioning and quality of life, and the last six questions address the issue
of treatment adherence (compliance). These two parts could be used separately as
dictated by the needs of an individual product.
SCOPE OF VIEWS .
The scale is primarily designed to assess the impact of antipsychotic medications during
schizophrenia treatment; however, it could be used in assessing people with other
psychiatric disorders who are receiving either pharmacological or psycho-social
interventions, or no treatment at all. Since the scale is meant to be a self-administered
instrument, it Is important to establish that the subject understands English and is
relatively stable in terms of adequate consultation and comprehension. Subjects who
are extremely disturbed with clinically thought disorder, distractibility, agitation or
potentially excessive behaviour are not suitable to complete the scale.
PROCESS OF ADMINISTRATION
Subjects should receive adequate introduction and instructions, prior to administration
to the scale. Subjects should be explained the purpose and the context of its use, and
should be warned about the time frame of the self-appraisal. The interviewer or
supervisor must be available during the period of administration, which Is likely to be
about 3 to 5 minutes. This will help the supervisor to observe the subject’s behaviour
during the completion and ensure the validity of the answers. Besides the supervisor
may help to clarify any doubts the subject may have about individual items. However,
the supervisor should not try to Interpret the meaning of the statements or suggest the
answers,
After the subject completes the questionnaire, the supervisor should make sure that all
the Items are checked. The supervlsor/intervlewer should also note the date and the
required identification data at the bottom of the scale.
SCORING INSTRUCTIONS
The scoring key Is enclosed. Each item could receive a score of 0, 1, or 2. Ratings
from the Individual Items are summed to come up with a total score. Total score for
the last six Items (the treatment adherence subscale) could be completed separately, as
per the needs of the investigators. If the subjects fail to answer any of the items, the
validity is likely to be seriously jeopardized.
APPLICATIONS
PETIT could be used during routine clinical practice or for the purposes of clinical
research. The scale Is sensitive enough to capture clinically meaningful differences
between one month and twelve months.
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PERSONAL EVALUATION OF TRANSITIONS IN TREATMENT

PETiT
We are interested in how you have been feeling and doing during the past ONE week.
Read each of the following statements. Choose the best answer that indicates your
feelings, and circle that option.
Please circle: Often
if you frequently feel or act in the way described in the
sentence,
Sometimes if you only feel or act that way occasionally, or
Never
if you had not felt or acted that way during the past week.

7. / am satisfied with my life
2. i am worried about what is happening to my health
3. i feel dull and sluggish
4. i believe that other people aren't comfortable around
me
5. i feel too tired to do things that / should do
6. i find it hard to come up new ideas
7. i am unable to trust people
8. My mind is sharp and dear
9. f am able to concentrate on reading or television
10. i am unhappy
7 7./ have family or friends who really understand me
7 2. My sex drive is weak
13.1 am able to communicate better with people
14. Chores such as cleaning, washing and shopping are
too much for me
15.! am able to remember things easily
16.1 feel ready to work either as a volunteer or for pay
77./ feel good about myself
18. My future seems gloomy
Page 1 of 2
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Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

19. i avoid meetinq new people
20. i feel weird and strange
21.1 can cope with the daily hassles of life
22. I dislike the way I look
23. 1 am not sieepinq well
24. / am able to do things as well as other people

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Finally, we would like to ask you some questions about your medication. Again
please indicate your response by circling the answer that best shows what you have
been feeling and doing.
25. 1 forget to take my medication
26. My medication is helping me
27. 1 dislike my current medication
28. Friends and family believe
medication is good for me.

that my current

29. Taking medication is unpleasant

. --------

30. / feel that the good things about taking medication
outweigh the bad
...----Thank you for your time.

Page 2 of 2
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Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Often

Sometimes

Never

Appendix M. Permission to use Schedule for the Assessment of Insight - Expanded.
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Institute of
Psychiatry
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AnthonyS David

Box 068

H»tir#payehlatry

Professor of Cognitive

Ob Crespigny Park

Division of

Neuropsychiatry

Denmark Htll
London SE68AF

RlstUdns

Tel +44(0)20 7848 0138

at The ifeuddey

Fax +44 (0)20 7846 0572

T/TNG’S
V\JJollege
LONDON

a.davfd@top.kd.ac.uX
www.top.kcl.ac.uk

University of London

11th January 2004

Stephanie Hall Ford
609 Southwest 19th Street
Fort Lauderdale
Florida 33315-2049
USA

Dear Stephanie,
Re: A randomised controlled trial of adherence therapy
Thank you for your request to use the Compliance Scale and Schedule for the
Assessment of Insight (SAI-E). I am happy to give consent for you to use these scales
in your trial.
I would he grateful if the scales are appropriately acknowledged in any resulting
publications.
If you wish to make further use of the scales following the completion of the trial I
would be grateful if you could contact me again for my consent.
With very best wishes.
Yours sincerely,

Anthony S David, MD FRCP, FRCPsych
ProfessorofCogiitive Neuropsychiatry

www.kcl.ac.uk

A joint division with the Guy's. King's 4 St Thomas' School of Medicine
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Appendix N. Liverpool University Neuroleptic Side-Effect Rating Scale.
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Very Much

39, Putting on weight
40. Restlessness
41 .Difficulty getting to sleep
42,Neck muscles aching
43,SboWness
44, Pins and needles
45, Palnful joints
46, Reduced sex drive
47, New or unusual skin marks
48, Parts of body moving of own accord.
Far avompte foot moving up ana Pawn,

49, Itchy skin
gO.Pertods tess frequent
51 .Passing a tot of water

145

LuMf3f^
Side Effect Prevalence in a sample of SO schizophrenic patients
Prevalence of side-effects In a sample of SO schizophrenic patients, distress associated with
side-effects In those patients who report them (0 = Not at ail; 1 = Very little; 2 = A little; 3=
Quit® a lot; 4 - very much) and percentage of patients experiencing side-effects who attribute
them to medication.

Side Effect
Tiredness
Dry mouth
Diff. remembering
Tension
Depression
Restlesness
Blurred vision
Diff. concentrating
Increased dreaming
Diff. getting to sleep
Passing a tot of water
Shakiness
Sensitivity to sun
Dyskinesia
Musd® stiffness
Pins and needles
Headaches
incresed sweating
Putting on weight
Slowing of movements
Diff, staying awake
Lack of emotions
Dizziness
Period problems
Sleeping to much
Constipation
Palpitations
Feeling sick
Musd© spasm
Reduced sex drive
Periods less frequent
Increased sex drive
Loosing weight
Rash
Itchy skin
Diff. achieving climax
Dianhoea
Drooflng mouth
Skin marks
Diff. passbig water
Gynaectmastta

Prevalence (%)
78
74
70
68
68
66
66
66
68
64
58
56
56
54
54
54
54
52
50
50
48
48
48
48
46
44
40
38
36
34
33
32
28
24
22
20
20
20
. 18
16
8

Distress +ve Attribution
2.353
1.400
1.970
2.552
2.533
2.000
1.893
2.280
1.500
2.250
1.556
1.S50
1.538
1.692
2.217
2.136
2.136
1.454
2.450
1.609
1.889
2.333
1.577
2.750
1.500
1.300
1.812
1.765
1.933
1.461
1.125
iai
1.312
1.133
1.850
2.250
2.333
2.429
1.375
2.500
1.714
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54
54
29
15
27
46
27
30
21
28
28
54
68
52
37
18
22
23
64
52
. 54
50
38
59
70
23
30
37
44
41
57
6
21
42
45
40
20
70
45
37
50

Appendix O. Media Consent/Release Form for audiotape.
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Mjami’tpublic raeành university

. HESaœNSENTFORM'
Media Consent & Keto»
Permission Is .hereby given to Stephanie Foul, a.Florida,International University graduate'
stater^ her agents, and persons or entitles hired or authorized by her, to make, or have
made, vote recordings and to use such vote recordings without compensation as
authorized by Stephanie Ford for educational and Instructional purposes only related
to the QAUTRO Adhdence Therapy study and program fidelity monitoring protocol,

I also understand that the original recording will be safeguarded in a secure, locked cabinet
to maintain my confidentiality and no Identifying information will be attached to the vote
recording tape. Therefore, I agree to Indemnify and hold harmless from any date
Stephanie Ford, her agents, and persons or entitles hired or authorized by her,

I understand the original audiotapes will be held In a locked, fireproof box at the graduate
student's residence for three years and then destroyed.

The undersigned hereby agrees to the terms and conditions of tills Agreement If subject Is
a minor (under 18 years of age), parent/guardian signature must be Included.

Signature:

................-----------——.—_____

Witness Name:_______ __________ ;_— ----- _____

Witness Signature:

___ _______ ____ _—----- —------------
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Therapist Fidelity Monitoring Protocol,
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QUATRO

ADHERENCE THERAPY SCALE
(Gray and Robson 2002 adapted from the cognitive therapy scale Vallis et al, 1986)

Directions:

For each item, assess the therapist on a scale from 0 to 3, and record the
rating in the space provided. Descriptions are given for each item.

1. Collaborative agenda setting
Score
0
1

2
3

Rating
□

. Anchor pointe
The therapist did not set an agenda

□
□

The therapist set an agenda that was vague or incomplete
The therapist worked with the patient to set a mutually satisfactory agenda
that included specific areas tor discussion.

□

The therapist worked with the patient to set an appropriate agenda with
specie and relevant areas for discussion suitable for the time avaiabie.
Established priorities and then followed this agenda

1 Feedback and understanding

0

Rating
□

Anchor pointe
Thé therapist did not ask for feedback to determine the patent's

1

□

understanding of, or response to, the session.
The therapist elicited some feedback from the patient, but did not ask «»ugh

Score

questions to be sure the patient understood the therapist's line of reasoning
during the session or to ascertain whether the patent was satisfied wfo the

2

□

session
The therapist asked enough questions to be sure that the patient understood
the therapist's line of reasoning throughout the session and to determine the
patient’s reactor» to the session. The therapist adjusted his/her behaviour in

3

□

response to the feedback, when appropriate.
The therapist was especially adept at eliciting and responding to feetoack
throughout the session {e.g. elicited reactions to session, regularly decked
for understanding, helped summarize main points at end of session).
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QUATRO

3.

Reflective listening

Score
0

Anchor points
The therapist repeatedly failed to reflect bade what the patient explicitly said

Rating
□

and thus consistently missed the point Poor empathic skills.
1

O

2

□

The therapist was usually able to reflect or paraphrase what the patient
explicitly said, but repeatedly failed to respond to more subtle
communication. Limited abfllty to listen and empathise.
The therapist generally seemed to grasp the patient’s "internal reality" as
reflected by both what the patient explicitly said and what the patient
communicated in more subtle ways. Good abfffty to listen, reflect and
empathise

3

4.

Collaboration

Score
0
1
2
3

5.

The therapist seemed to understand the patient's 'internal reality" thoroughly
and was adept at communicating this understanding through appropriate
responses to the patient (e.g. the tones of the therapist's response conveyed
an empathic understanding of the patient’s "message")

O

Anchor points

Rating
O
□

The therapist did not work in a collaboratively way with the patient
The therapist attempted to collaborate with the patient but had difficulty
establishing rapport
The therapist was able to collaborate with the patient and establish rapport
Collaboration seemed excellent; the therapist encouraged the patient as
much as. possible to fake an active role during the session (e.g. by offering
choices) so they could function as a "team".

□
□

Pacing and efficient

um of time

Score
0

ting
□

Anchor points
The therapist made no attempt to structure therapy time. The session

1

□

seemed aimless.
The session had some direction, but the therapist had significant problems
with structuring or pacing (e.g„ too little structure, inflexible about structure,

2

□

3

□

too siowty paced, too rapidly paced).
The therapist was reasonably successful at using tíme efficiently. The
.

therapist maintained appropriate control over flow of discussion and pacing
The therapist used time efficiently by tactfully liming peripheral and
unproductive discussion and by pacing the session as rapidly as was
appropriate for the patient
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QUATRO

6.

Developing discrepancy

Score

Rating

0

O

Anchor pointe
The therapist relied primarily on debate, persuasion, or the didactic

1

□

presentation of information.
The therapist relied too heavily on persuasion and debate, rather than
developing discrepancy. However, the therapist's style was supportive
enough that the patent did not seem to feel attacked or defensive.

2

□

The therapist, for the most part, helped the patient to see new a perspective
through developing discrepancy (e.g., examining evidence, considering
alternatives, exploring ambivalence) rather than through debate. Used

3

□

questioning appropriately.
The therapist was especially adept at developing discrepancy during the
session. Achieved an excellent balance between skilful questioning and
other modes of Intervention.

7.

Dealing with resistance

Score
0

Rating
□

Anchor points
The therapist did not use any strategies to work with resistance

1

□

The therapist made an attempt to work with resistance but tended towards

2

□

confrontation and argument
The therapist, for the most part, used effective strategies to work with
resistance (e.g. reflective listening, emphasis on personal choice and control,
reassessing readiness, importance and confidence, backing off and coming
along side the patient).

3

O

The therapist was extremely skilled at working with resistance during the
session. Made excellent use of a range of strategies.

8. Application of adherence therapy techniques (Note: For this Hem, focus on how skilfully
the techniques were applied, not on how appropriate they were or whether change actually
OCGUtTWF}.
Score
0

Rating
O

1

□

2
3

□
□

Anchor points
The therapist did not apply any recognisable adherence therapy techniques.
The therapist used adherence therapy techniques, but there were
significant flaw in the way they were applied.
The therapist applied adherence therapy techniques with moderate skill.
The therapist wry skilfully and resourcefully employed adherence therapy
techniques.

Total score (add items 1-8 together)

__________

In your opinion was this patient receiving
□

Adherenoe therapy

□

Health education

O

Don’t know/unaure

On« completed plea» send a espy to Rfchard Grey, at the Health Smte« Research Department, I nsttlute of

Psyshiaty, De Cresplgiy Park, London, UK.
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Appendix Q, QAT Program Satisfaction Questionnaire
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QAT PROGRAM SATISFACTION QUESTIONNAIRE
Please circle the response that most closely describes bow you feel right now.
5
1. I learned more about how I manage my mental health:

Strongly

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure

Disagree

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure

Disagree

Strongly

Agree

Not Sure,

Disagree

Strongly

Disagree

Agree
2. I had a chance to ask questions I always wanted to ask.

Strongly

Disagree

Agree
3. I learned more about my treatment for mental health.

Strongly

Disagree

Agree
4. I didn’t learn anything new about my treatment for mental

Strongly

health

Agree

5. 1 understand more about how the medication 1 take affects

Strongly

me
6. My counselor was helpful to me.

Agree
Strongly

Disagree
Disagree
Disagree

Agree
7. I enjoyed being a part of the study.

Strongly

Disagree

Agree
8. People in the study treated me with respect

Strongly

Disagree

Agree
9.1 am satisfied with this counseling study.

Strongly

Agree

Not Sure

Disagree

Agree

Not Sure

Disagree

Strongly

Strongly

Agree

Not Sure

Disagree

Strongly
Disagree

Disagree

Agree
11.1 have a better understanding of how to take care of my

Strongly

mental illness

Agree

The best things about the counseling study are:

A list of toe things I wish had been different in this counseling study:
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Strongly
Disagree

Agree
10.1 would recommend this type of counseling to a friend.

Strongly

Appendix R.

Human Participation Protections Certification for all Study Members
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UW Human Subjects Training Certification'
Print this page as a record of completing the Human Subjects Protection Training
To print, select Print from the File menu, or hit the printer icon on your toolbar.
This certifies that KATHRYN ANDERSON completed the UW computer-based
training on human subjects protection on 5/28/2003.
‘ ’
For specific questions on human subjects protection or IRB related policies,
check the Protection of Human Subject in Research website
or contact one of the following IRB offices:
Health Sciences Center IRB
This IRB reviews all research protocols involving medical interventions or procedures where
medical expertise is required for evaluation.
Contact: Nichelle Cobb, Ph.D., Acting Director, 262-1980
Office: Judith Brickbauer, Program Assistant, 263 -2362
IRB Chair: Norman Fost, M.D., M.P.H., Professor, Pediatrics, 263-8562
Social and Behavioral Sciences IRB
This IRB reviews social, behavioral, and non-medical health research. It does not have
appropriate expertise for review of medical research, but may review research protocols
involving minimal risk health-related studies, such as those involving exercise, tape sensors,
and single venipuncture, where medical training is not necessary for the evaluation of risk to
research subjects.
Contact; Donna Jahgke, Assistant Dean, 263-2320
IRB Chair: Jon Miller, Ph.D., Professor, Communicative Disorders, 262-6461
Education Research IRB
This IRB specializes in education research. It does not have appropriate expertise for review of
medical research, but may review research protocols, involving minimal risk health-related
studies, such as those involving exercise, tape sensors, and finger sensors, where medical
training is not necessary for the evaluation of risk to research subjects.
Contact: Kari Walsh, 262-9710
IRB Chair: Allan Cohen, Ph.D., Associate Professor, Educational Psychology, 262-5863

Research .and Sponsored Programs Homepage
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Completion Certificate
This is to certify that

jean ansourian
has completed the Human Participants Protection Education for Research Teams
online course, sponsored by the National Institutes of Health (NIH), on 10/19/2003,
This course included the following:
• key historical events and current issues that impact guidelines and legislation on
human participant protection in research.
• ethical principles and guidelines that should assist in resolving the ethical issues
inherent in the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect human participants
at various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent.
• a description of the role of the IRB in the research process.
• the roles, responsibilities, and interactions of federal agencies, institutions, and
researchers in conducting research with human participants.

National Institutes of Health
http://www.nih,gov

http://cme.cancer.gov/cgi-bin/cms/cts-cert5 .pi

10/19/2003

159

¡ùffifm 'FanißWant Frotéctiônô Eâucàtton for Ft

--.h ; ams

Completion Certificate
This is to certify that

Patricia Brinson
has completed the Human Participants Protection Education for Research Teams online course,
sponsored by the National Institutes of Health (NIH), on 10/25/2003.
This course included the following:
• key historical events and current issues that impact guidelines and legislation on human
participant protection in research.
» ethical principles and guidelines that should assist in resolving the ethical issues inherent in
the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect human participants at
various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent.
• a description of the role of the IRB in the research process.
• the roles, responsibilities, and interactions of federal agencies, institutions, and researchers in
conducting research with human participants.

National Institutes of Health
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Homan Participant Protections
Completion Certificate
This is to certify that

marie fairchild
has completed the Human Participants Protection Education for Research Teams
online course, sponsored by the National Institutes of Health (NIH), on 10/27/2003.
This course included the following:
• key historical events and current issues that impact guidelines and legislation on
human participant protection in research.
• ethical principles and guidelines that should assist In resolving the ethical issues
inherent in the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect human participants
at various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent.
• a description of the role of the 1RB in the research process.
• the roles, responsibilities, and interactions of federal agencies, institutions, and
researchers in conducting research with human participants.

National Institutes of Health
http://www.nih. uov

10/27/2003

ht^p://cme.cancer.gt>v/cg»-bm/cms/cts-cert5.pl
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Completion Certificate
This is to certify that

Stephanie Ford
has completed the Human Participants Protection Education for
Research Teams online course, sponsored by the National
Institutes of Health (NIH), on 10/03/2003.
This course included the following:
• key historical events and current issues that impact guidelines
and legislation on human participant protection in research.
• ethical principles and guidelines that should assist in resolving
the ethical issues inherent in the conduct of research with
human participants.
• the use of key ethical principles and federal regulations to
protect human participants at various stages in the research
process.

• a description of guidelines for the protection of special
populations in research.
• a definition of informed consent and components necessary for
a valid consent.
• a description of the role of the IRB in the research process.
• the roles, responsibilities, and interactions of federal agencies,
institutions, and researchers in conducting research with human
participants.

■ National Institutes of Health
http://www.nih.gov
10/3/2003

http://cme.cancer.gov/cgi-bin/cms/cts-cert5.pl

162

Completion Certificate
This is to certify that

Richard Gray
has completed the Human Participants Protection Education for Research Teams
online course, sponsored by the National Institutes of Health (NIH), on 02/18/2004.
This course included the following.
• key historical events and current issues that impact guidelines and legislation on
human participant protection in research.
• ethical principles and guidelines that should assist in resolving the ethical issues
inherent in the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect human participants
at various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent.
• a description of the role of the IRB in the research process.
• the roles, responsibilities, and interactions of federal agencies, institutions, and
researchers in conducting research with human participants.

National Institutes of Health

p://cme.cancer.igov/cgi-bin/cnw/cts-cert5.pi
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Jcipant Protections Educ

Completion Certificate
This is to certify that
Tara Haley
has completed the Human'Participants Protection Education for Research Teams
online course, sponsored by the National Institutes of Health (NIH), on 02/09/2004.
This course included the following:
• key historical events and current issues that impact guidelines and legislation on
human participant protection in research.
• ethical principles and guidelines that should assist in resolving the ethical issues
inherent in the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect human participants
at various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent
• a description of the role ofthelRB in the research process.
• the roles, responsibilities, and interactions of federal agencies, institutions, and
researchers in conducting research with human participants.

National Institutes of Health

2/9/2004
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Completion Certificate
This is to certify that
maria« oksengorn
has completed the Human' Participants Protection Education for Research Teams
online course, sponsored by the National Institutes of Health (NIH), on 02/09/2004.
This course included the following:
• key historical events and current issue» that impact guidelines and legislation on
human participant protection in research.
• ethical principles and guidelines that should assist in resolving the ethical issues
inherent in the conduct of research with human participants.
• the use of key ethical principles and federal regulation» to protect human participants
at various stages in die research process.
• a description of guidelines far the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent.
• a description of the role of the IRS in the research process.
« the roles, responsibilities, and interactions of federal agencies, institutions, and
researchers in conducting research with human participants.

National Institutes of Health
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Completion Certiticate

This is to certify that

DebWe Robson
has completed the Human Participants Protection Education for Research Teams online course,
sponsored by the National Institutes of Health (NIH), on 03/24/2004.
This course included the following:
• key historical events and current issues that impact guidelines and legislation on human
participait protection in research.
■ • ethical principles and guidelines that should assist in resolving the ethical issues inherent in
the conduct of research with human participants.
• the use of key ethical principles and federal regulations to protect humai participants at
various stages in the research process.
• a description of guidelines for the protection of special populations in research.
• a definition of informed consent and components necessary for a valid consent
• a description of the role ofthelRB in the research process.
.• the roles, responsibilities, and interactions of federal agencies, institutions, and researchers in
conducting research with human participants.

National Institutes of Health
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If your client agrees to tape record a session, you and your client will sign a form saying it is okay to tape
record the session.
You will receive clinical supervision from Dr. Kathy Anderson on site as arranged by you and you will
participate in further supervision with Dr.-Richard Gray or Deborah Robson individually as agreed during
the training session.
The principle investigator, Stephanie Ford, and research assistent, Patricia Brinson will be blinded to the
control or experimental status of all study subjects. You agree to maintain the confidentiality of subject’s
identity and refrain from discussion of the study and subjects participation in counseling except in private
supervision sessions.
Stephanie H. Ford, the principle investigator, is available for any questions at 954,483.0457 or
754.581.2844.
If you have further questions and want to talk to someone at Florida International University about this
study, please contact Dr. Kathy Anderson at 1-305-919-5376. If you still have questions and need to talk
further, you can call Dr. Bernard Gerstman. He is the Chairperson of the Florida International University,
Institutional Review Board. His phone number is 1-305-348-3115 or 1-305-348-2494.

By signing your name below on this form, you are saying that all of your questions have been answered in
a way you like and that you understand what your responsibilities are In the study. Your signature on this
form also indicates that you have an understanding of your rights and that you would like to participate in
this study.

Signature of Participant

Printed Name

-

Date

I have explained the research procedure and subject rights. I have answered aK questions asked by the
participant I have offered the participant named above a copy-of this informed' toosenlferm.

Signature of Witness

Printed Nane

Date

appbovbd
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